Tricyclic compounds, preparation thereof and therapeutic uses as ERK5 inhibitors

Abstract

Compounds are provided which can inhibit ERK5. Also provided are pharmaceutical compositions and medical uses of the same, including the use in treating or preventing conditions such as cancers. Formula (I)

Description

[0001] PAT24007-WO-PCT TRICYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF Compounds are provided which can inhibit ERK5. Also provided are pharmaceutical compositions and medical uses of the same, including the use in treating or preventing conditions such as cancers. SUMMARY The mitogen-activated protein kinase (MAPK) cascade is a highly-conserved cellular pathway which transmits signals from the cell surface to the nucleus. The pathway plays an important role in cell proliferation, differentiation, and migration and it is well known to be involved in the development of cancer. Proteins in the pathway include the extracellular signal-regulated kinase (ERK) proteins; among those, ERK5 (expressed from the MAPK7 gene) plays an important role in cell proliferation, as well as epithelial development and neural differentiation (see, e.g., Nishimoto et al., EMBO Reports (2006) 7(8):782-786). ERK5 is unique among the ERK proteins, having a large C-terminal domain which contains a transcriptional activation domain (TAD) as well as a nuclear localization signal and two proline-rich regions (see, e.g., Guo et al., Exp Ther Med. (2020) 19:1997-2007). Autophosphorylation of the TAD is required for transcriptional activation (see, e.g., Morimoto et al., J Biol Chem. (2007) 282(49):35449-35456). ERK5 plays an important role in controlling cell proliferation and cell cycle progression, for example via direct or indirect phosphorylation of MEF2C, cMYC, SGK1, RSK, FOS, and FRA1 among others (see, e.g., Paudel et al., Int J Mol Sci. (2021) 22:7594-7614; Terasawa et al., Genes to Cells (2003) 8(3):263-273). The involvement of ERK5 in numerous biological pathways means that its activity is associated with many aspects of cancer progression, including tumour angiogenesis, metastasis, inflammation, sustained proliferation, and evasion of growth suppression. It therefore presents an attractive target for modulating disease pathology and treatment in a wide range of conditions. In previous studies, ERK5 inhibition or down-regulation has been shown to block tumorigenesis in murine leukaemia cells, reduce growth of chronic myeloid leukaemia cells, inhibit growth of breast cancer and multiple myeloma cells, suppress colon cancer cell proliferation, and have to have an impact on renal cell carcinoma, mesothelioma, adenocarcinoma, neuroblastoma and hepatocellular carcinoma cell growth or survival, among others (see, e.g., Stecca et al., Int J Mol Sci. (2019) 20:1426- 1446). ERK5 inhibition thus represents a promising approach to tackle a broad range of cancers. Several ERK5 inhibitors have been developed and some are under clinical review. For PAT24007-WO-PCT example, WO 2019 / 170543 (Bayer AG and Bayer Pharma AG) discloses compounds which are said to be active as ERK5 inhibitors in the µM to nM concentration range. Despite recent progress in cancer treatment with the development of targeted therapies and immunotherapies, not all cancer patients can be offered an efficient therapeutic solution. There is therefore a need to identify and develop new drugs. The present disclosure seeks to address this need by providing novel compounds for use as ERK5 inhibitors and for the treatment of ERK5 related diseases and conditions. Accordingly, a first aspect provides a compound, being of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: ring A is (C5-C8)cycloalkane, (C6-C8)cycloalkene, or 5- to 8-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RA, wherein RAat each occurrence is: (a) independently selected from -D, halo, -OH, oxo, =N-OH, -NHR’, -CN, -C(O)R’’, -(C1-C3)alkyl, -O(C1-C3)alkyl, -(C3- C6)cycloalkyl, and 3- to 6-membered heterocycloalkyl, wherein each occurrence of -(C1-C3)alkyl is optionally substituted with one or more groups selected from halo and -OH, wherein each R’ is selected from -H, -(C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and 3- to 4-membered heterocycloalkyl, wherein each R’’ is selected from -OH, -O(C1-C3)alkyl, and -(C1- C3)alkyl (e.g. -CH3); and / or (b) taken together with another occurrence of RAand the intervening atom(s) to form a (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring and said cycloalkyl ring are optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1- C3)alkyl)2, and -(C1-C3)alkyl; PAT24007-WO-PCT R1is selected from -H, and halo (e.g., -F); R2is -(C6-C10)aryl, wherein R2is substituted with one, or two occurrences of RB, wherein each RBis independently selected from halo, -OH, -NH2, -SF5, -(C1-C3)alkyl, and -O(C1-C3)alkyl, wherein each occurrence of -(C1-C3)alkyl and -O(C1-C3)alkyl is optionally substituted by one or more halo; and n is 0, 1, or 2, with the proviso that when R2is 4-(pentafluorosulfanyl)phenyl, R1is -H, and n is 1, then ring A is not unsubstituted cyclopentane. In embodiments, ring A is selected from cyclopentane, cyclohexane, cycloheptane, cyclooctane, tetrahydrofuran, tetrahydropyran, piperidine, morpholine, oxepane, azepane, 1,4-oxazepane, and thiepane, wherein ring A is optionally substituted with one or more occurrences of RAas defined hereinbefore. , PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof, wherein: ring A is (C5-C8)cycloalkane or 6- to 7-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RA, wherein RAat each occurrence is: (a) independently selected from -OH, oxo, -NHR’, -C(O)CH3, -(C1- C3)alkyl, and -O(C1-C3)alkyl, wherein each R’ is selected from -(C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and 3- to 4-membered heterocycloalkyl; or (b) taken together with another occurrence of RAand the intervening atom(s) to form a (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo; R1is selected from -H, and -F; RB1is selected from -H, and -NH2;and RB2is selected from -OCF3, and -SF5, with the proviso that when RB1is -H, RB2is -SF5, and R1is -H, then ring A is not unsubstituted cyclopentane. In embodiments, RB2is -OCF3. PAT24007-WO-PCT In embodiments, R1is -F. Another aspect provides a compound, being of Formula (III), Formula (IV), Formula (V), or Formula (VI): or a pharmaceutically acceptable salt thereof, wherein ring A and R1are as defined hereinbefore, with the proviso that when the compound is a compound of Formula (V) and R1is -H, then ring A is not unsubstituted cyclopentane. A further aspect provides a compound selected from the group consisting of: - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-7-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(12-fluoro-5-oxa-8,10- diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-13-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-oxetane]-4-yl)-1-piperidyl]methanone; PAT24007-WO-PCT - [4-[(12R)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(12S)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-5,7,8,9- tetrahydropyrido[2,3-b]indol-6-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - (6R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one; - (6S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one; - [4-[(3R,8R)-13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(3S,8S)-13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-((2S, 7S)-12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-((2R, 7R)-12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-oxa-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-13-methyl-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-6,8- diazatricyclo[7.6.0.02,7]pentadeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-(1-hydroxy-1-methyl- ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-(1-hydroxy-1-methyl- ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(1-hydroxy-1-methyl- ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; PAT24007-WO-PCT - (7R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile; - (7S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-1'-methyl-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-azetidine]-4-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6E)-3-fluoro-6-hydroxyimino-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6Z)-3-fluoro-6-hydroxyimino-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [4-[(5R)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(5S)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7E)-3-fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7Z)-3-fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12E)-4-fluoro-12-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12Z)-4-fluoro-12-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13E)-4-fluoro-13-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13Z)-4-fluoro-13-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(5R)-3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(5S)-3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3R,8R)-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3S,8S))-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7R)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7S)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7R)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7S)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [4-[(6R)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [4-[(12R)-4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(12S)-4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7R)-3-fluoro-7-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7S)-3-fluoro-7-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - 1-[4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-yl]ethanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-7-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; PAT24007-WO-PCT - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [4-[(13R)-4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(13S)-4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-fluoro-11,11-dimethyl-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one; - [4-[(6R)-6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol- 4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [4-[(7E)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(7Z)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11R,15S)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11S,15R)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - (6R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - (6S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-12-deuterio-4-fluoro-12-hydroxy- 6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1- piperidyl]methanone; and PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-12-deuterio-4-fluoro-12-hydroxy- 6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1- piperidyl]methanone, and the pharmaceutically acceptable salts thereof. A further aspect provides a pharmaceutical composition comprising the compound defined hereinbefore and at least one pharmaceutically acceptable excipient or carrier. A further aspect provides a compound, or a pharmaceutical composition, as defined hereinbefore for use in therapy. A further aspect provides a compound, or a pharmaceutical composition, as defined hereinbefore for use in the treatment or prevention of cancer. In embodiments, the cancer is characterized by increased MAPK7 expression and / or increased ERK5 activity. In embodiments, the cancer is selected from leukaemia, breast cancer, multiple myeloma, colon cancer, colorectal cancer, lung cancer, pancreatic cancer, renal cell carcinoma, mesothelioma, adenocarcinoma, neuroblastoma, melanoma, and hepatocellular carcinoma. DETAILED DESCRIPTION Although specific embodiments of the present disclosure will now be described with reference to the description and examples, it should be understood that such embodiments are by way of example only and merely illustrative of but a small number of the many possible specific embodiments which can represent applications of the principles of the present disclosure. Various changes and modifications will be obvious to those of skill in the art given the benefit of the present disclosure and are deemed to be within the spirit and scope of the present disclosure as further defined in the appended claims. Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, exemplary methods, devices, and materials are now described. All technical and patent publications cited herein are incorporated herein by reference in their entirety. PAT24007-WO-PCT The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of chemical synthesis, tissue culture, immunology, molecular biology, microbiology, cell biology, recombinant DNA, etc., which are within the skill of the art. See, e.g., Michael R. Green and Joseph Sambrook, Molecular Cloning (4thed., Cold Spring Harbor Laboratory Press 2012); the series Ausubel et al. eds. (2007) Current Protocols in Molecular Biology; the series Methods in Enzymology (Academic Press, Inc., N.Y.); MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach; Harlow and Lane eds. (1999) Antibodies, A Laboratory Manual; Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5thedition; Gait ed. (1984) Oligonucleotide Synthesis; U.S. Patent No. 4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization; Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos eds. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Herzenberg et al. eds (1996) Weir’s Handbook of Experimental Immunology; Manipulating the Mouse Embryo: A Laboratory Manual, 3rdedition (Cold Spring Harbor Laboratory Press (2002)); Sohail (ed.) (2004) Gene Silencing by RNA Interference: Technology and Application (CRC Press). All numerical designations, e.g., pH, temperature, time, concentration, molecular weight, etc., including ranges, are approximations which are varied ( + ) or ( - ) by increments of, e.g., 0.1 or 1.0, where appropriate. It is to be understood, although not always explicitly stated, that all numerical designations are preceded by the term “about”, which is used to denote a conventional level of variability. For example, a numerical designation which is “about” a given value may vary by ± 10% of said value; alternatively, the variation may be ± 5%, ± 2%, or ± 1% of the value. It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art. As used in the specification and claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof. Unless specifically stated or obvious from context, as used herein, the term “or” is understood to be inclusive. The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to”. As used herein, the term “comprising” or “comprises” is intended to mean that the compositions and methods include the recited elements, without excluding other elements. PAT24007-WO-PCT “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this disclosure or process steps to produce a composition or achieve an intended result. Embodiments defined by each of these transition terms are within the scope of this disclosure. Use of the term “comprising” herein is intended to encompass, and to disclose, the corresponding statements in which the term “comprising” is replaced by “consisting essentially of” or “consisting of”. A “subject,” “individual”, or “patient” is used interchangeably herein, and refers to a vertebrate, such as a mammal. Mammals include, but are not limited to, rodents, farm animals, sport animals, pets, and primates; for example murines, rats, rabbit, simians, bovines, ovines, porcines, canines, felines, equines, and humans. In a particular embodiment, the mammal is a human. “Administering” is defined herein as a means of providing an agent or a composition containing the agent to a subject in a manner that results in the agent being contacted with (e.g., being inside) the subject’s body. Such an administration can be by any route including, without limitation, oral, transdermal (e.g., by the vagina, rectum, or oral mucosa), by injection (e.g., subcutaneous, intravenous, parenteral, intraperitoneal, or into the central nervous system), or by inhalation (e.g., oral or nasal). Administration may also involve providing a substance or composition to a part of the surface of the subject’s body, for example by topical administration to the skin. Pharmaceutical preparations are, of course, given by forms suitable for each administration route. “Treating” or “treatment” of a disease includes: (1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a patient that may be predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e. arresting or reducing the development of the disease or its clinical symptoms; and / or (3) relieving the disease, i.e. causing regression of the disease or its clinical symptoms. The term “suffering” as it relates to the term “treatment” refers to a patient or individual who has been diagnosed with or is predisposed to the disease. A patient may also be referred to being “at risk of suffering” from a disease because of a history of disease in their family lineage or because of the presence of genetic mutations associated with the disease. A patient at risk of a disease has not yet developed all or some of the characteristic pathologies of the disease. PAT24007-WO-PCT An “effective amount” or “therapeutically effective amount” is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications, or dosages. Such delivery is dependent on a number of variables including the time period for which the individual dosage unit is to be used, the bioavailability of the therapeutic agent, the route of administration, etc. It is understood, however, that specific dose levels of the therapeutic agents of the present disclosure for any particular subject depends upon a variety of factors including, for example, the activity of the specific compound employed, the age, body weight, general health, sex, and diet of the subject, the time of administration, the rate of excretion, the drug combination, the severity of the particular disorder being treated and the form of administration. Treatment dosages generally may be titrated to optimize safety and efficacy. Typically, dosage-effect relationships from in vitro and / or in vivo tests initially can provide useful guidance on the proper doses for patient administration. In general, one will desire to administer an amount of the compound that is effective to achieve a serum level commensurate with the concentrations found to be effective in vitro. Determination of these parameters is well within the skill of the art. These considerations, as well as effective formulations and administration procedures are well known in the art and are described in standard textbooks. Consistent with this definition, as used herein, the term “therapeutically effective amount” is an amount sufficient to treat (e.g., improve) one or more symptoms associated with the condition. The total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. As used herein, the terms "increased" and "elevated" are used interchangeably and encompass any measurable increase in a biological function and / or a biological activity and / or a concentration. For example, an increase can be by at least about 10%, e.g. at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, such as at least about 95%, 96%, 97%, 98%, 99%, or 100%. Thus, an increase can be by at least about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold, such as at least about 20-fold, 25-fold, 50-fold, 100-fold, or higher, relative to a control or baseline amount or function, or activity, or concentration. As used herein, the terms "increased expression" and / or "increased activity" of a substance, such as ERK5, in a sample or cancer or patient, typically refers to an increase in the amount of the substance (e.g., of the MAPK7 gene product or ERK5 protein), although it may also denote an increase in the biological activity of the substance (e.g., constitutive activation of phosphorylation and / or reduced discrimination of phosphorylation sites of ERK5). For example, an increase can be by an amount of about 5%, e.g., about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, such as about 96%, 97%, 98%, 99%, or 100%. Thus, the increase can be about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold, such as about 20-fold, 25-fold, 50-fold, 100- PAT24007-WO-PCT fold, or higher, relative to the amount (or activity) of the substance, such as ERK5, in a control sample or control samples, such as an individual or group of individuals who are not suffering from the disease or disorder (e.g. cancer) or an internal control, as determined by techniques known in the art. A subject can also be determined to have an "increased expression” or "increased activity" of ERK5 if the expression and / or activity of ERK5 is increased by one standard deviation, two standard deviations, three standard deviations, four standard deviations, five standard deviations, or more, relative to the mean (average) or median amount of ERK5 in a control group of samples or a baseline group of samples or a retrospective analysis of patient samples. As practiced in the art, such control or baseline expression levels can be previously determined, or measured prior to the measurement in the sample or cancer or subject, or can be obtained from a database of such control samples. As used herein, the term “pharmaceutically acceptable excipient” encompasses any of the standard pharmaceutical excipients, for example as described in Remington’s Pharmaceutical Sciences (20th ed., Mack Publishing Co.2000). Such excipients include carriers such as a phosphate buffered saline solution, water, and emulsions, such as an oil / water or water / oil emulsion, and various types of wetting agents. Pharmaceutical compositions also can include stabilizers, preservatives, adjuvants, fillers, binders, lubricants, and the like. As used herein, the term “alkyl” means a saturated linear or branched free radical consisting essentially of carbon atoms and a corresponding number of hydrogen atoms. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, etc. Other alkyl groups will be readily apparent to those of skill in the art given the benefit of the present disclosure. The terms “(C1-C3)alkyl”, “(C1-C6)alkyl”, etc., have equivalent meanings, i.e., a saturated linear or branched free radical consisting essentially of 1 to 3 (or 1 to 6) carbon atoms and a corresponding number of hydrogen atoms. The definition of “alkyl” also applies in the context of other groups which comprise alkyl groups, such as “-O(C1-C3)alkyl”. The term “haloalkyl” means an alkyl group which is substituted by one or more halogens. Exemplary haloalkyl groups include trifluoromethyl, trifluoroethyl, difluoroethyl, pentafluoroethyl, chloromethyl, etc. One or more carbon atoms in the backbone of the alkyl group may be substituted by (or bonded to) a heteroatom by a multiple bond (e.g., a double bond); for example, a carbon atom of the alkyl group may be bonded to oxygen via a double bond (i.e., substituted by oxo to provide a carbonyl function). The presence of such a substituent does not prevent the carbon backbone of the free radical being considered as an alkyl group. As used herein, the term “cyclic group” means a saturated, partially or fully unsaturated, or aromatic group having at least 3 to 10 atoms (i.e., ring atoms) that form a ring. Where a cyclic group is defined as having a certain number of members, the term “members”, “membered” and the like is used to denote the number of ring atoms in said cyclic group. For example, a 5-membered cyclic group (e.g., a 5-membered heterocyclic group) contains 5 ring PAT24007-WO-PCT atoms. It will be appreciated that a cyclic group may be part of a larger cyclic system; for example, bicyclo[4.3.0]nonane comprises two carbocyclic groups, namely a cyclohexane group and a cyclopentane group, which are fused to form the carbocyclic system which makes up the molecule. The term “cyclic group” is intended to encompass both carbocyclic groups as well as heterocyclic groups. The term “carbocyclic” refers to a group having at least 3 to 9 carbon atoms that form a ring. The term “heterocyclic” refers to a group having at least 3 to 10 atoms that form a ring, wherein at least 1 to 9 of said ring atoms are carbon and the remaining at least 1 to 9 ring atom(s) (i.e., hetero ring atom(s)) are selected independently from the group consisting of nitrogen, sulphur, and oxygen. The term “spiro” or “spirocyclic” as used herein in relation to cyclic groups denotes that a first cyclic group within a multicyclic system is attached to a second cyclic group within said multicyclic system, wherein the ring atoms of said first cyclic group and the ring atoms of said second cyclic group have only one atom in common, i.e., said first and second cyclic groups share only one common ring atom. For example, the spiro[5.5]undecanyl group comprises two cyclohexyl rings which have a single carbon ring atom in common. The term “fused” as used herein in relation to cyclic groups denotes that a first cyclic group within a multicyclic system is attached to a second cyclic group within said multicyclic system, wherein the ring atoms of said first cyclic group and the ring atoms of said second cyclic group have two adjacent atoms in common, i.e., said first and second cyclic groups share two common ring atoms. For example, the bicyclo[4.4.0]decanyl group comprises two cyclohexyl rings which have two adjacent carbon ring atoms in common. The term “bridged” as used herein in relation to cyclic groups denotes that a first cyclic group within a multicyclic system is attached to a second cyclic group within said multicyclic system, wherein the ring atoms of said first cyclic group and the ring atoms of said second cyclic group have more than two adjacent atoms in common, i.e., said first and second cyclic groups share three or more common ring atoms. For example, the bicyclo[3.3.1]nonanyl group comprises two cyclohexayl rings which have three adjacent carbon ring atoms in common. Within the structural formulae described herein, any ring system (including any spiro, fused, or bridged ring system) may be connected to other parts of a molecule through any atom having suitable valency. For example, a bicyclic ring may be connected to another part of the molecule through a ring atom (e.g., a secondary carbon atom or heteroatom such as N), or a bridgehead (e.g., a tertiary carbon atom). Spiro, fused, and bridged rings may be fully unsaturated, partially unsaturated, or fully saturated, and may have aromatic character in one or more of their constituent rings. PAT24007-WO-PCT As used herein, the term “cycloalkane” means a saturated cyclic group having at least 3 to 9 carbon atoms (i.e., ring atoms) that form a ring moiety, wherein the cycloalkane moiety is fused to another cyclic group. Cycloalkane moieties described herein (e.g., ring A of Formula (I)) are typically fused to aromatic rings (e.g., the pyrrole ring depicted in Formula (I)) through common carbon atoms. The presence of unsaturation (e.g., a bond having aromatic character) in the fused portion does not prevent the cyclic group being considered as a cycloalkane moiety. The term “(C5-C8)cycloalkane” means a saturated cyclic group which contains a total of 5, 6, 7, or 8 ring carbon atoms, wherein the cycloalkane moiety is fused to another cyclic group. One or more ring atoms of the cycloalkane group may be substituted by (i.e., bonded to) a heteroatom by a double bond (e.g., cycloalkane substituted by oxo). The presence of such a substituent does not prevent the cyclic group being considered as a cycloalkane moiety. Exemplary cycloalkane moieties include cyclopentane, cyclohexane, cycloheptane, and cyclooctane. As used herein, the term “cycloalkene” means an unsaturated cyclic group having at least 5 to 9 carbon atoms (i.e., ring atoms) that form a ring moiety, wherein the cycloalkene moiety is fused to another cyclic group. Cycloalkene moieties described herein (e.g., ring A of Formula (I)) are typically fused to aromatic rings (e.g., the pyrrole ring depicted in Formula (I)) through common carbon atoms. The presence of unsaturation (e.g., a bond having aromatic character) in the fused portion is not determinative in considering the cyclic group as a cycloalkene moiety. For the avoidance of doubt, in addition to the bond having unsaturated character in the fused portion, the cycloalkene ring also has additional unsaturation. The term “(C6-C8)cycloalkene” means an unsaturated cyclic group which contains a total of 6, 7, or 8 ring carbon atoms, wherein the cycloalkene moiety is fused to another cyclic group. One or more ring atoms of the cycloalkene group may be substituted by (i.e., bonded to) a heteroatom by a double bond (e.g., cycloalkene substituted by oxo). The presence of such a substituent does not prevent the cyclic group being considered as a cycloalkene moiety. An exemplary cycloalkene moiety is cycloheptene. As used herein, the term “cycloalkyl” means a saturated cyclic group (e.g., a saturated free radical) having at least 3 to 9 carbon atoms (i.e., ring atoms) that form a ring. A cycloalkyl group may be a cycloalkyl ring, in which the ring is connected to another cyclic group in a spiro, fused, or bridged configuration, or it may be a cycloalkyl substituent, in which the ring is connected by one exocyclic bond to another atom. For example, a cycloheptane moiety may be substituted by two substituents which taken together form a bridgehead, such that the cycloheptane and the substituents taken together form a bicyclo[3.2.1]octane. The term “(C4- C7)cycloalkyl” denotes that the cycloalkyl group contains a total of 4, 5, 6, or 7 carbon atoms in the ring portion of the group, for example cyclohexyl (having 6 ring carbon atoms). One or more ring atoms of the cycloalkyl group may be substituted by (i.e., bonded to) a heteroatom by a double bond (e.g., cycloalkyl substituted by oxo). The presence of such a substituent PAT24007-WO-PCT does not prevent the cyclic group being considered as a cycloalkyl group. Cycloalkyl groups may be monocyclic or multicyclic (e.g., bicyclic). In embodiments, the cycloalkyl group is monocyclic. Exemplary cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, and cycloheptyl. As used herein, the term “aryl” means an aromatic free radical having at least 6 carbon atoms (i.e., ring atoms) that form a ring. It will be appreciated that the aryl group may be monocyclic or multicyclic (e.g., fused). Examples of aryl groups include phenyl and naphthalenyl. The term “(C6-C10)aryl” denotes that the aryl group contains from 6 to 10 carbon atoms in the ring portion of the group. In embodiments, (C6-C10)aryl is phenyl. As used herein, the term “heterocycloalkane” means a saturated cyclic group having at least 3 to 10 atoms (i.e., ring atoms) that form a ring moiety, wherein at least 1 to 9 of said ring atoms are carbon and the remaining at least 1 to 9 ring atom(s) (i.e., hetero ring atom(s)) are selected independently from the group consisting of nitrogen, sulphur, and oxygen, wherein the heterocycloalkane moiety is fused to another cyclic group. Heterocycloalkane moieties described herein (e.g., ring A of Formula (I)) are typically fused to aromatic rings (e.g., the pyrrole ring depicted in Formula (I)) through common carbon atoms. The presence of unsaturation (e.g., a bond having aromatic character) in the fused portion does not prevent the cyclic group being considered as a heterocycloalkane moiety. In embodiments, the hetero ring atom(s) are selected independently from the group consisting of nitrogen and oxygen. Where a heterocycloalkane moiety is described as being “X- to Y-membered” (where X and Y are integers), this means that the heterocycloalkane moiety contains a total number of ring atoms from X to Y. For example, the term “5- to 8-membered heterocycloalkane” means a saturated cyclic group which contains a total of 5, 6, 7, or 8 ring atoms, of which one or more is a hetero ring atom, wherein the heterocycloalkane moiety is fused to another cyclic group. One or more ring atoms of the heterocycloalkane group may be substituted by (i.e., bonded to) a heteroatom by a double bond (e.g., heterocycloalkane substituted by oxo), but the heteroatom does not form part of the ring and is excluded from the number of ring atoms. Such substituents (e.g., oxo groups) are typically located adjacent to a heteroatom (e.g., in the case of 2-oxepanone, also known as caprolactone, or 2-azepanone, also known as caprolactam). Any ring sulphur atom may optionally carry one or more pendant (i.e., non- ring) oxygen atoms, as found in, e.g., a sulfolanyl group. The presence of any such substituents do not prevent the cyclic group being considered as a heterocycloalkane moiety. Exemplary heterocycloalkane moieties include tetrahydropyran, piperidine, oxepane, and azepane. As used herein, the term “heterocycloalkyl” means a saturated cyclic group (e.g. a saturated free radical) having at least 3 to 10 atoms (i.e., ring atoms) that form a ring, wherein at least 1 to 9 of said ring atoms are carbon and the remaining at least 1 to 9 ring atom(s) (i.e., hetero PAT24007-WO-PCT ring atom(s)) are selected independently from the group consisting of nitrogen, sulphur, and oxygen. A heterocycloalkyl group may be a heterocycloalkyl ring, in which the ring is connected to another cyclic group in a spiro, fused, or bridged configuration, or it may be a heterocycloalkyl substituent, in which the ring is connected by one exocyclic bond to another atom. In embodiments, the hetero ring atom(s) are selected independently from the group consisting of nitrogen and oxygen. Where a heterocycloalkyl group is described as being “X- to Y-membered” (where X and Y are integers), this means that the heterocycloalkyl group contains a total number of ring atoms from X to Y. For example, the term “4- to 7-membered heterocycloalkyl” means a saturated cyclic group which contains a total of 4, 5, 6, or 7 ring atoms, of which one or more is a hetero ring atom, for example tetrahydropyranyl (6 ring atoms). Heterocycloalkyl groups may have oxo substituents, typically adjacent to a heteroatom (e.g., 2-oxopyrrolidinyl), but the oxygen atom of the oxo group does not form part of the ring and is excluded from the number of ring atoms. The presence of such a substituent does not prevent the cyclic group being considered as a heterocycloalkyl group. Any ring sulphur atom may optionally carry one or more pendant (i.e., non-ring) oxygen atoms, as found in, e.g., a sulfolanyl group. Heterocycloalkyl groups may be monocyclic or multicyclic (e.g., bicyclic). In embodiments, the heterocycloalkyl group is monocyclic. Exemplary heterocycloalkyl groups include oxetanyl, tetrahydrofuranyl, piperidinyl, and morpholinyl. As used herein, the terms “halo” and “halogen” mean fluorine, chlorine, bromine, or iodine. These terms are used interchangeably and may refer to a halogen free radical group or to a halogen atom as such. Those of skill in the art will readily be able to ascertain the identification of which in view of the context in which this term is used in the present disclosure. In embodiments, the halogen is fluorine. As used herein, the term “CN” means a free radical having a carbon atom linked to a nitrogen atom via a triple bond. The CN radical is attached via its carbon atom. As used herein, the term “oxo” means a free radical wherein an oxygen atom is connected to the atom bearing this radical via a double bond. For example, where a carbon atom carries an oxo radical it forms a carbon-oxygen double bond. It will be appreciated that not all atoms within a given structure can be substituted by oxo, and that this will depend on the free valency of the atom to be substituted. The compounds of the present disclosure are described, inter alia, by way of structural formulae. It will be appreciated that these formulae typically show only one form (e.g., resonance form, tautomeric form, etc.) of the compound, whereas certain compounds may exist in more than one such form. This will be readily apparent to the skilled reader. The present disclosure includes all possible tautomers of the compounds characterised by the PAT24007-WO-PCT structural formulae herein, including as single tautomers, or as any mixture of tautomers in any ratio. For example, a pyrrolopyridine moiety (as shown, e.g., in Formula (I), and which may be referred to as 1H-pyrrolo[2,3-b]pyridine or 7-azaindole) may be illustrated by any of the below tautomeric forms, which are used interchangeably throughout this description: It will also be one or more isomeric stereoisomers, enantiomers, diastereomers, etc. of the compounds described hereinbefore and below, as well as cis- and trans- forms and conformers of the same. The purification and the separation of isomers may be accomplished by methods described hereinafter, as well as by techniques known in the art. For example, optical isomers of the compounds can be obtained by resolution of the racemic mixture of diastereoisomeric salts thereof (e.g., using an optically active acid or base, or by the formation of covalent diastereomers). A different process for separation of optical isomers involves the use of chiral chromatography (e.g., HPLC columns using a chiral phase), with or without conventional derivatization. Enzymatic separation, with or without derivatisation, may also be useful, and optically active compounds of the present disclosure can likewise be obtained by chiral syntheses utilizing optically active starting materials. The present disclosure includes all possible stereoisomers of the compounds described herein as single stereoisomers, or as any mixture of said stereoisomers, e.g. (R)- or (S)- isomers, in any ratio. The compounds of the disclosure may exist in the form of free acids or bases, or may exist as addition salts with suitable acids or bases. Methods for forming salts are described below and are also known in the art (see, e.g., Berge et al., J Pharm Sci. (1977) 66:1-19). As used herein, the term “pharmaceutically acceptable” when used in connection with salts means a salt of a currently disclosed compound that may be administered without any resultant substantial undesirable biological effect(s) or any resultant deleterious interaction(s) with any other component of a pharmaceutical composition in which it may be contained. A group defined as “optionally substituted” may be either unsubstituted, or substituted with one or more substituents, e.g.1, 2, 3, 4, 5, 6, or more substituents. In embodiments, a substituted group has 1 to 4 substituents, e.g.1, 2, or 3 substituents. In embodiments, a substituted group has 1 or 2 substituents. In embodiments, a substituted group has 3 substituents. PAT24007-WO-PCT The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. Compositions and methods provided herein may be combined with one or more of any of the other compositions and methods provided herein. The following abbreviations and empirical formulae are used herein: Ac acetyl AE ethyl acetate ATP adenosine triphosphate tert-butyloxy carbonyl DABCO 1,4-diazabicyclo[2.2.2]octane DAD diode-array detection DCM dichloromethane DIBAL-H diisobutylaluminium hydride DIPEA diisopropylethylamine DMA dimethylacetamide DMF N,N-dimethylformamide DMSO dimethyl sulfoxide 4EBP1 eukaryotic translation initiation factor 4E-binding protein 1 EDC / EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide ERK extracellular signal-regulated kinase ESI electrospray ionisation EtOAc / AcOEt ethyl acetate FRET Forster resonance energy transfer HATU hexafluorophosphate azabenzotriazole tetramethyl uronium HOBt hydroxybenzotriazole HPLC high performance liquid chromatography LC liquid chromatography LC / MS liquid chromatography / mass spectrometry LDA lithium di-isopropylamide MAPK mitogen-activated protein kinase MS mass spectrometry MTBE methyl tert-butyl ether NBS N-bromosuccinimide NCS N-chlorosuccinimide NIS N-iodosuccinimide PAT24007-WO-PCT NMP N-methyl-2-pyrrolidone Pd / C palladium on carbon PdCl2(dppf) [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) PE petroleum ether PIFA [bis(trifluoroacetoxy)iodo]benzene Pin 2,3-dimethyl-2,3-butanediolate PTFE poly(tetrafluoroethylene) rac racemic mixture RPMI Roswell Park Memorial Institute medium SEM 2-trimethylsilylethoxymethyl SFC supercritical fluid chromatography SGC silica gel chromatography TAD transcriptional activation domain TATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide tetrafluoroborate TBS tert-butyldimethylsilyl TBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TosMIC toluenesulfonylmethyl isocyanide TPP 5,10,15,20-tetraphenyl-21H,23H-porphyrin / meso- tetraphenylporphyrin Ts 4-toluenesulfonyl (tosyl) UPLC ultra-high performance liquid chromatography UV ultraviolet Compounds In a first aspect the present disclosure provides a compound being of Formula (I) PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof, wherein: ring A is (C5-C8)cycloalkane, (C6-C8)cycloalkene, or 5- to 8-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RA, wherein RAat each occurrence is: (a) independently selected from -D, halo, -OH, oxo, =N- OH, -NHR’, -CN, -C(O)R’’, -(C1-C3)alkyl, -O(C1-C3)alkyl, -(C3- C6)cycloalkyl, and 3- to 6-membered heterocycloalkyl, wherein each occurrence of -(C1-C3)alkyl is optionally substituted with one or more groups selected from halo and -OH, wherein each R’ is selected from -H, -(C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and 3- to 4-membered heterocycloalkyl, wherein each R’’ is selected from -OH, -O(C1-C3)alkyl, and -(C1- C3)alkyl (e.g. -CH3); and / or (b) taken together with another occurrence of RAand the intervening atom(s) to form a (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring and said cycloalkyl ring are optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1- C3)alkyl)2, and -(C1-C3)alkyl; R1is selected from -H, and halo (e.g., -F); R2is -(C6-C10)aryl, wherein R2is substituted with one, or two occurrences of RB, wherein each RBis independently selected from halo, -OH, -NH2, -SF5, -(C1-C3)alkyl, and -O(C1-C3)alkyl, wherein each occurrence of -(C1-C3)alkyl and -O(C1-C3)alkyl is optionally substituted by one or more halo; and n is 0, 1, or 2, with the proviso that when R2is 4-(pentafluorosulfanyl)phenyl, R1is -H, and n is 1, then ring A is not unsubstituted cyclopentane. In another aspect the present disclosure provides a compound being of Formula (I) PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof, wherein: ring A is (C5-C8)cycloalkane or 5- to 8-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RA, wherein RAat each occurrence is: (a) independently selected from halo, -OH, oxo, -NHR’, -CN, -C(O)R’’, -(C1-C3)alkyl, -O(C1-C3)alkyl, -(C3- C6)cycloalkyl, and 3- to 6-membered heterocycloalkyl, wherein each occurrence of -(C1-C3)alkyl is optionally substituted with one or more halo or - OH, wherein each R’ is selected from -H, -(C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and 3- to 4-membered heterocycloalkyl, wherein each R’’ is selected from -OH and -CH3; and / or (b) taken together with another occurrence of RAand the intervening atom(s) to form a (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo; R1is selected from -H, and halo (e.g., -F); R2is -(C6-C10)aryl, wherein R2is substituted with one, or two occurrences of RB, wherein each RBis independently selected from halo, -OH, -NH2, -SF5, -(C1-C3)alkyl, -O(C1-C3)alkyl, wherein each occurrence of -(C1-C3)alkyl and -O(C1-C3)alkyl is optionally substituted by one or more halo; and n is 0, 1, or 2, with the proviso that when R2is 4-(pentafluorosulfanyl)phenyl, R1is -H, and n is 1, then ring A is not unsubstituted cyclopentane. When one occurrence of RAis taken together with another occurrence of RAto form a (C4- C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring and said cycloalkyl ring are optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1-C3)alkyl)2, and -(C1-C3)alkyl, then the (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring may be bonded to ring A in a spiro, fused, or bridged configuration. In embodiments, one occurrence of RAis taken together with another occurrence of RAto form a (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring and said cycloalkyl ring are substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1-C3)alkyl)2, and -(C1-C3)alkyl, and wherein the (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring is bonded to ring A in a spiro configuration. When one occurrence of RAis taken together with another occurrence of RAto form a (C4- C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring PAT24007-WO-PCT is optionally substituted by oxo, the (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring may be bonded to ring A in a spiro, fused, or bridged configuration. In embodiments, ring A is (C5-C8)cycloalkane or 5- to 7-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is (C5-C8)cycloalkane, wherein ring A is optionally substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is cyclopentane, cyclohexane, cycloheptane, or cyclooctane, wherein ring A is optionally substituted with one or more occurrences of RA. In embodiments, ring A is (C5-C7)cycloalkane, wherein ring A is optionally substituted with one or more occurrences of RA. In embodiments, ring A is cyclopentane, cyclohexane, or cycloheptane, wherein ring A is optionally substituted with one or more occurrences of RA. In embodiments, ring A is (C5-C6)cycloalkane, wherein ring A is substituted by one or more occurrences of RAas defined herein. In embodiments, ring A is (C5-C6)cycloalkane, wherein ring A is substituted by one, or two occurrences of RAas defined herein. In embodiments, ring A is (C5-C6)cycloalkane substituted with two occurrences of RA, wherein the two occurrences of RAare taken together with the intervening carbon atom(s) to form a 4- to 6- membered heterocycloalkyl ring. In embodiments, ring A is (C6-C8)cycloalkene, wherein ring A is optionally substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is cycloheptene, e.g. unsubstituted cycloheptene. In embodiments, ring A is 5- to 8-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is 5- to 7-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is 6- to 7-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RAas defined herein. In embodiments, the heterocycloalkane contains two heteroatoms (e.g. independently selected from a nitrogen, oxygen or sulfur atom) within its ring. In embodiments, the heterocycloalkane contains two heteroatoms (e.g. independently selected from a nitrogen or oxygen or sulfur atom) within its ring. In embodiments, the heterocycloalkane contains two heteroatoms within its ring, wherein one of the heteroatoms is a nitrogen atom and the other is selected from oxygen and sulfur. In embodiments, the first heteroatom is nitrogen and the second heteroatom is oxygen. In embodiments, the heterocycloalkane contains one heteroatom within its ring, wherein the heteroatom is selected from a nitrogen atom, an PAT24007-WO-PCT oxygen atom and a sulfur atom. In embodiments, the heterocycloalkane contains one heteroatom (e.g. a nitrogen or oxygen atom) within its ring. In embodiments, the heterocycloalkane contains one heteroatom within its ring, wherein the heteroatom is a nitrogen atom, and the heterocycloalkane comprises an RAsubstituent which is selected from halo, -OH, oxo, -C(O)R’’, -(C1-C3)alkyl, -(C3-C6)cycloalkyl, and 3- to 6- membered heterocycloalkyl, wherein each occurrence of -(C1-C3)alkyl is optionally substituted with one or more groups selected from halo, wherein each R’’ is selected from -(C1-C3)alkyl (e.g. -CH3). In embodiments, the RAsubstituent is bonded to the nitrogen atom within the heterocycloalkane ring. In embodiments, said RAsubstituent is selected from -CH3, -CH2CF3, cyclopropyl, and oxetanyl (e.g., -oxetan-3-yl). In embodiments, the heterocycloalkane comprises an RAsubstituent which is oxo. In embodiments, the heterocycloalkane contains one heteroatom (e.g. a nitrogen or oxygen atom) within its ring, and the heterocycloalkane comprises an RAsubstituent which is oxo, wherein the oxo is bonded to a carbon atom adjacent to the heteroatom (e.g. adjacent to the nitrogen or oxygen atom). In embodiments, the heterocycloalkane comprises a sulfur atom within its ring, and the heterocycloalkane comprises two RAsubstituents which are oxo, wherein the oxo substituents are both bonded to the sulfur atom (i.e. to form a cyclic sulfone group). In embodiments, the heterocycloalkane contains two heteroatoms within its ring (e.g. wherein the two heteroatoms are bonded to each other), wherein one heteroatom is a sulfur atom and the other heteroatom is a nitrogen atom, and the heterocycloalkane comprises two RAsubstituents which are oxo, wherein the oxo substituents are both bonded to the sulfur atom (i.e. to form a cyclic sulfonamide group). In embodiments, ring A is selected from cyclopentane, cyclohexane, cycloheptane, cyclooctane, cycloheptene, tetrahydrofuran, tetrahydropyran, piperidine, morpholine, oxepane, azepane, 1,4-oxazepane, and thiepane, wherein ring A is optionally substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is selected from cyclopentane, cyclohexane, cycloheptane, cyclooctane, tetrahydrofuran, tetrahydropyran, piperidine, morpholine, oxepane, azepane, 1,4-oxazepane, and thiepane, wherein ring A is optionally substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is cyclohexane substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is cycloheptane substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is cyclooctane substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is oxepane substituted with one or more occurrences of RAas defined herein. In embodiments, ring A is azepane substituted with one or more occurrences of RAas defined herein. PAT24007-WO-PCT ,,is In embodiments, ring A is substituted with one or more occurrences of RA, wherein RAat each occurrence is independently selected from -D, halo, -OH, oxo, =N- OH, -NHR’, -CN, -C(O)R’’, -(C1-C3)alkyl, -O(C1-C3)alkyl, -(C3-C6)cycloalkyl, and 3- to 6- membered heterocycloalkyl; wherein each occurrence of -(C1-C3)alkyl is optionally substituted with one or more groups selected from halo and -OH; wherein each R’ is selected from -H, -(C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and PAT24007-WO-PCT 3- to 4-membered heterocycloalkyl; and wherein each R’’ is selected from -OH, -O(C1- C3)alkyl, and -(C1-C3)alkyl (e.g. -CH3). In embodiments, ring A is substituted with one or more occurrences of RA, wherein RAat each occurrence is independently selected from halo, -OH, oxo, -NHR’, -CN, -C(O)R’’, -(C1- C3)alkyl, -O(C1-C3)alkyl, -(C3-C6)cycloalkyl, and 3- to 6-membered heterocycloalkyl; wherein each occurrence of -(C1-C3)alkyl is optionally substituted with one or more halo or -OH; wherein each R’ is selected from -H, -(C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and 3- to 4-membered heterocycloalkyl; and wherein each R’’ is selected from -OH and -CH3. In embodiments, ring A is substituted with one or more occurrences of RA, wherein RAat each occurrence is independently selected from -D, halo (e.g., F), -OH, oxo, =N- OH, -NHR’, -CN, -C(O)R’’, -CH3, -CF3, -CH2CF3, -CH2OH, - C(CH3)2CH2OH, -OCH3, -cyclopropyl, oxetanyl (e.g., oxetan-3-yl), and morpholinyl (e.g., 4- morpholinyl); wherein each R’ is selected from -H, -CH2CH2F, cyclopropyl, and oxetanyl (e.g., oxetan-3-yl); and wherein each R’’ is selected from -OH, -OCH3, and -CH3. In embodiments, ring A is (C6-C7)cycloalkane, wherein ring A is substituted by one occurrence of RA, wherein RAis =N-OH (i.e., an oxime). In embodiments, the oxime is a mixture of E and Z isomers. In embodiments, the oxime is an E oxime. In other embodiments, the oxime is a Z oxime. In embodiments, ring A is substituted with one or more occurrences of RA, wherein RAat each occurrence is independently selected from halo, -OH, oxo, -NHR’, -CN, -C(O)R’’, -CH3, -CF3, -CH2CF3, -CH2OH, -OCH3, -cyclopropyl, and - oxetanyl (e.g., -oxetan-3-yl); wherein each R’ is selected from -H, -CH2CH2F, -cyclopropyl, and -oxetanyl (e.g., -oxetan-3-yl); and wherein each R’’ is selected from -OH and -CH3. In other embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring and said cycloalkyl ring are optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1-C3)alkyl)2, and -(C1-C3)alkyl. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo. The (C4-C7)cycloalkyl or 4- to 7- membered heterocycloalkyl ring may be connected to ring A in a spiro, fused, or bridged configuration. PAT24007-WO-PCT In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1- C3)alkyl)2, and -(C1-C3)alkyl. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo. In embodiments, the (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring is connected to ring A in a spiro, or fused configuration. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a 4- to 7-membered heterocycloalkyl ring, wherein the 4- to 7-membered heterocycloalkyl ring is connected to ring A in a spiro, or fused configuration, and wherein said heterocycloalkyl ring is optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1-C3)alkyl)2, and -(C1-C3)alkyl. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a 4- to 7-membered heterocycloalkyl ring, wherein the 4- to 7-membered heterocycloalkyl ring is connected to ring A in a spiro, or fused configuration, and wherein said heterocycloalkyl ring is optionally substituted by oxo. In other embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atoms to form a (C4-C7)cycloalkyl ring, wherein the (C4-C7)cycloalkyl ring is connected to ring A in a bridged configuration. In embodiments, the (C4-C7)cycloalkyl ring is substituted with one or more -OH groups. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring and said cycloalkyl ring are optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1-C3)alkyl)2, and -(C1-C3)alkyl. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat each occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo. In embodiments, the (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring is connected to ring A in a spiro, fused, or bridged configuration. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a 4- to 6-membered heterocycloalkyl ring, and wherein said heterocycloalkyl PAT24007-WO-PCT ring is optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1-C3)alkyl)2, and -(C1-C3)alkyl. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a 4- to 6-membered heterocycloalkyl ring, and wherein said heterocycloalkyl ring is optionally substituted by oxo. In embodiments, the (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring is connected to ring A in a spiro, or fused configuration. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is connected to ring A in a spiro, or fused configuration, and wherein said heterocycloalkyl ring is optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1-C3)alkyl)2, and -(C1-C3)alkyl. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is connected to ring A in a spiro, or fused configuration, and wherein said heterocycloalkyl ring is optionally substituted by oxo. In embodiments, the heterocycloalkyl ring is selected from oxetanyl, azetidinyl optionally substituted by methyl (e.g., N-methylazetidinyl), tetrahydrofuranyl, dioxolanyl, pyrrolidinyl optionally substituted by oxo (e.g., 2-pyrrolidinonyl), tetrahydropyranyl, piperidinyl, and morpholinyl. In embodiments, the heterocycloalkyl ring is selected from oxetanyl, azetidinyl, tetrahydrofuranyl, dioxolanyl, pyrrolidinyl optionally substituted by oxo (e.g., 2- pyrrolidinonyl), tetrahydropyranyl, piperidinyl, and morpholinyl. In other embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atoms to form a (C5-C7)cycloalkyl ring, wherein the (C5-C7)cycloalkyl ring is connected to ring A in a bridged configuration. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a (C4-C7)cycloalkyl ring, wherein said (C4-C7)cycloalkyl ring is optionally substituted by one or more groups selected from oxo, -C(O)OH, -C(O)N((C1- C3)alkyl)2, and -(C1-C3)alkyl. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a (C4-C7)cycloalkyl ring, wherein said (C4-C7)cycloalkyl ring is optionally substituted by one or more groups selected from oxo, -C(O)OH, and -C(O)N((C1- C3)alkyl)2. In embodiments, the (C4-C7)cycloalkyl ring is selected from cyclobutyl optionally substituted by oxo (e.g., cyclobutan-2-onyl), -C(O)OH, and -C(O)N(CH3)2. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other occurrence of RAand the intervening atom(s) to form a (C4- PAT24007-WO-PCT C7)cycloalkyl ring, wherein said (C4-C7)cycloalkyl ring is connected to ring A in a spiro, bridged, or fused configuration, and wherein said cycloalkyl ring is optionally substituted by one or more groups selected from oxo, -C(O)OH, and -C(O)N((C1-C3)alkyl)2. In embodiments, ring A is unsubstituted. In embodiments, ring A is unsubstituted (C6- C8)cycloalkane. In embodiments, ring A is unsubstituted cyclohexane. In embodiments, ring A is unsubstituted cycloheptane. In embodiments, ring A is unsubstituted cyclooctane. In embodiments, ring A is unsubstituted 7-membered cycloalkene. In embodiments, ring A is unsubstituted 5- to 7-membered heterocycloalkane. In embodiments, ring A is unsubstituted 5-membered heterocycloalkane. In embodiments, ring A is unsubstituted 6-membered heterocycloalkane. In embodiments, ring A is unsubstituted 7-membered heterocycloalkane. In other embodiments, ring A is substituted with one, two, or three occurrences of RAas defined herein. In embodiments, ring A is substituted with one, or two occurrences of RAas defined herein. In embodiments, ring A is substituted with one occurrence of RA. In embodiments, ring A is substituted with two occurrences of RA. In embodiments, ring A is substituted with three occurrences of RA. In embodiments, each occurrence of -(C1-C3)alkyl for the group RAis optionally substituted by one or more -OH groups, e.g. is independently selected from -CH2OH and -C(CH3)2OH. In embodiments, each occurrence of -(C1-C3)alkyl for the group RAis independently methyl or ethyl, optionally substituted by one or more halo or -OH. In embodiments, each occurrence of -(C1-C3)alkyl optionally substituted by one or more halo for the group RAis independently selected from -CH3, -CF3, and -CH2CF3. In embodiments, each occurrence of 3- to 6-membered heterocycloalkyl for the group RAis independently morpholinyl (e.g., 4-morpholinyl). In embodiments, each occurrence of -(C1-C3)alkyl for the group R’ is independently ethyl optionally substituted by one or more halo. In embodiments, each occurrence of -(C1-C3)alkyl optionally substituted by one or more halo for the group R’ is independently -CH2CH2F. In embodiments, each occurrence of -(C3-C4)cycloalkyl for the group R’ is independently -cyclopropyl. In embodiments, each occurrence of 3- to 4-membered heterocycloalkyl for the group R’ is independently -oxetanyl (e.g., -oxetan-3-yl). In embodiments, each occurrence of -O(C1-C3)alkyl for the group R’’ is independently -OCH3. In embodiments, each occurrence of -(C1-C3)alkyl for the group R’’ is independently -CH3. PAT24007-WO-PCT , 5 , PAT24007-WO-PCT ,, , , ,5 PAT24007-WO-PCT ,5 PAT24007-WO-PCT , , the PAT24007-WO-PCT ,5 , PAT24007-WO-PCT 5

[0002] PAT24007-WO-PCT ,5 PAT24007-WO-PCT , wherein the dashed bonds indicate the depict ring A and the one or more In embodiments, R1is -H. In embodiments, R1is halo. In embodiments, R1is -F. In embodiments, R2is -(C6-C10)aryl substituted with one, or two occurrences of RBas defined herein. In embodiments, R2is -(C6-C10)aryl substituted with one occurrence of RB. In embodiments, R2is -(C6-C10)aryl substituted with two occurrences of RB. In embodiments, R2is phenyl substituted with one, or two occurrences of RBas defined herein. In embodiments, R2is phenyl substituted with one occurrence of RB. In embodiments, R2is phenyl substituted with two occurrences of RB. In embodiments, each RBis independently selected from halo (e.g., -F), -OH, -NH2, -SF5, and -O(C1-C3)alkyl optionally substituted by one or more halo (e.g., -F). In embodiments, each RBis independently selected from halo (e.g., -F), -OH, -NH2, and -O(C1-C3)alkyl optionally substituted by one or more halo (e.g., -F). In embodiments, each RBis independently selected from -NH2, -SF5, and -O(C1-C3)alkyl optionally substituted by one or more halo (e.g., -F). In embodiments, each occurrence of -O(C1-C3)alkyl for the group RBis independently -O(methyl) optionally substituted by one or more halo. In embodiments, each occurrence of -O(C1-C3)alkyl optionally substituted by one or more halo for the group RBis independently -OCF3. In embodiments, each RBis independently selected from -NH2, -SF5, and -OCF3. In embodiments, each RBis independently selected from -NH2, and -OCF3. In embodiments, R2is -(C6-C10)aryl substituted with one, or two occurrences of RB, wherein each RBis independently selected from -NH2, -SF5, and -OCF3. In embodiments, R2is -(C6- C10)aryl substituted with one, or two occurrences of RB, wherein each RBis independently selected from -NH2, and -OCF3. In embodiments, R2is phenyl substituted with one, or two occurrences of RB, wherein each RBis independently selected from -NH2, -SF5, and -OCF3. In embodiments, R2is phenyl substituted with one, or two occurrences of RB, wherein each RBis independently selected from -NH2, and -OCF3. In embodiments, R2is phenyl substituted with two occurrences of RB, wherein one occurrence of RBis -NH2, and the other occurrence of RBis selected from -SF5and -OCF3. In embodiments, R2is phenyl substituted with two occurrences of RB, wherein one occurrence of RBis -NH2, and the other occurrence of RBis -OCF3. In embodiments, R2is phenyl substituted with one occurrence of RB, wherein RBis -OCF3. PAT24007-WO-PCT is embodiments, n is 1. In embodiments, n is 2. In embodiments, R1is -F and n is 1. In embodiments, the compound is a compound of Formula (II) or a pharmaceutically acceptable salt thereof, wherein ring A and R1are as defined herein, RB1is selected from -H and RBas defined herein, and RB2is selected from RBas defined herein. In embodiments, RB1is selected from -H and -NH2. In embodiments, RB2is selected from -OCF3, and -SF5(e.g. -OCF3). In embodiments, RB1is selected from -H and -NH2, and RB2is -OCF3. In embodiments, the compound is a compound of Formula (II) PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof, wherein: ring A is (C5-C8)cycloalkane or 6- to 7-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RA, wherein RAat each occurrence is: (a) independently selected from -OH, oxo, -NHR’, -C(O)CH3, -(C1- C3)alkyl, and -O(C1-C3)alkyl, wherein each R’ is selected from -(C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and 3- to 4-membered heterocycloalkyl; or (b) taken together with another occurrence of RAand the intervening atom(s) to form a (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo; R1is selected from -H, and -F; RB1is selected from -H, and -NH2;and RB2is selected from -OCF3, and -SF5, with the proviso that when RB1is -H, RB2is -SF5, and R1is -H, then ring A is not unsubstituted cyclopentane. In embodiments, ring A is (C5-C8)cycloalkane or 6- to 7-membered heterocycloalkane, wherein ring A is optionally substituted with one or two occurrences of RAas defined herein. In embodiments, ring A is selected from cyclopentane, cyclohexane, cycloheptane, cyclooctane, tetrahydropyran, piperidine, oxepane, and azepane, wherein ring A is optionally substituted with one or more occurrences (e.g., one or two occurrences) of RAas defined herein. PAT24007-WO-PCT , , wherein the dashed bonds indicate the points of is optionally substituted by one or more of RAas defined herein. herein. In embodiments, RAat each occurrence is independently selected from -OH, oxo, -NHR’, -C(O)CH3, -CH3, and -OCH3, wherein each R’ is selected from - CH2CH2F, -cyclopropyl, and -oxetanyl (e.g., -oxetan-3-yl). In other embodiments, two occurrences of RAare taken together with the intervening atom(s) to form a (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo. In embodiments, ring A is unsubstituted. In embodiments, ring A is unsubstituted (C6- C8)cycloalkane. In embodiments, ring A is unsubstituted 5- to 6-membered heterocycloalkane. In other embodiments, ring A is substituted with one, or two occurrences of RAas defined herein. In embodiments, ring A is substituted with one occurrence of RA. In embodiments, ring A is substituted with two occurrences of RA. In embodiments, ring A is substituted with two occurrences of RA, wherein RAat one occurrence is taken together with the other PAT24007-WO-PCT occurrence of RAand the intervening atom(s) to form a (C5-C7)cycloalkyl or 4- to 6- membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo. The (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring may be bonded to ring A in a spiro, fused, or bridged configuration. In embodiments, ring A is substituted with two occurrences of RAwhich are taken together with the intervening atom(s) to form a 4- to 6-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo. The 4- to 6-membered heterocycloalkyl ring may be bonded to ring A in a spiro, fused, or bridged configuration. In embodiments, ring A is substituted with two occurrences of RAwhich are taken together with the intervening atom(s) to form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is bonded to ring A in a spiro, or fused configuration, and wherein said heterocycloalkyl ring is optionally substituted by oxo. In embodiments, the 4- to 6-membered heterocycloalkyl ring comprises one or two ring heteroatoms independently selected from O and N. In embodiments, the 4- to 6-membered heterocycloalkyl ring is selected from oxetanyl, azetidinyl, tetrahydrofuranyl, dioxolanyl, pyrrolidinyl optionally substituted by oxo (e.g., 2-pyrrolidinonyl), tetrahydropyranyl, and piperidinyl. In embodiments, ring A is substituted with two occurrences of RAwhich are taken together with the intervening atom(s) to form a (C5-C7)cycloalkyl ring, wherein the (C5-C7)cycloalkyl ring is bonded to ring A in a bridged configuration. In embodiments, each occurrence of -(C1-C3)alkyl for the group RAis independently -CH3. In embodiments, each occurrence of -O(C1-C3)alkyl for the group RAis independently -OCH3. In embodiments, each occurrence of -(C1-C3)alkyl for the group R’ is independently ethyl, optionally substituted by one or more halo. In embodiments, each said occurrence of -(C1- C3)alkyl for the group R’ is independently -CH2CH2F. In embodiments, each occurrence of -(C3-C4)cycloalkyl for the group R’ is independently -cyclopropyl. In embodiments, each occurrence of 3- to 4-membered heterocycloalkyl for the group R’ is independently -oxetanyl (e.g., -oxetan-3-yl). In embodiments, the compound is a compound of Formula (II) or a pharmaceutically acceptable salt thereof, wherein: ring A is (C5-C8)cycloalkane or 6- to 7-membered heterocycloalkane, wherein ring A is optionally substituted with one or two occurrences of RA, wherein RAat each occurrence is: (a) independently selected from -OH, oxo, -NHR’, -C(O)CH3, -CH3, and -OCH3, PAT24007-WO-PCT wherein each R’ is selected from -CH2CH2F, -cyclopropyl, and -oxetanyl (e.g., -oxetan-3-yl); or (b) taken together with another occurrence of RAand the intervening atom(s) to form a (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo; R1is selected from -H, and -F; RB1is selected from -H, and -NH2;and RB2is selected from -OCF3, and -SF5, with the proviso that when RB1is -H, RB2is -SF5, and R1is -H, then ring A is not unsubstituted cyclopentane. , PAT24007-WO-PCT , In embodiments, R1is -F. In embodiments, RB1is -H. In other embodiments, RB1is -NH2. In embodiments, RB2is -OCF3. In embodiments, RB1is -H, and RB2is -OCF3. In other embodiments, RB1is -NH2, and RB2is -OCF3. In embodiments, RB1is -NH2 and RB2is -SF5. In embodiments, the compound is a compound of Formula (III) or Formula (IV) or a pharmaceutically acceptable salt thereof, wherein ring A and R1are as defined herein. In embodiments, the compound is a compound of Formula (III), or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is a compound of Formula (IV), or a pharmaceutically acceptable salt thereof. In embodiments, R1is -H. In embodiments, R1is -F. PAT24007-WO-PCT In embodiments, the compound is a compound of Formula (V) or a pharmaceutically acceptable salt thereof, wherein ring A and R1are as defined herein, with the proviso that when R1is -H, then ring A is not unsubstituted cyclopentane. In embodiments, R1is -H. In embodiments, R1is -F. In embodiments, the compound is a compound of Formula (VI) or a pharmaceutically acceptable salt thereof, wherein ring A and R1are as defined herein. In embodiments, R1is -H. In embodiments, R1is -F. In embodiments, the compound is selected from the group consisting of: - [4-[3-fluoro-6-(2-fluoroethylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,14- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-one; - trans-[4-[13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - trans-[4-[4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - trans-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [4-[6-(cyclopropylamino)-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,4'- piperidine]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-oxetane]-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - [4-(3-fluoro-5,6,8,9-tetrahydrospiro[pyrido[2,3-b]indole-7,2'-dioxolan]-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-5,6,8,9- tetrahydropyrido[2,3-b]indol-7-one; - [4-(3-fluoro-6-hydroxy-6-methyl-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,3'-tetrahydrofuran]-12-yl]- 1-piperidyl]methanone; - 1-[12-fluoro-13-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4,8,10- triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-4-yl]ethanone; - [4-[11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,3'- tetrahydrofuran]-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluoro-6-(2-fluoroethylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(12-fluoro-3-oxa-8,10- diazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11-tetraen-13-yl)-1-piperidyl]methanone; - [4-(12-fluoro-3-oxa-8,10-diazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11-tetraen-13- yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - cis-[4-[4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - cis-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(12-fluoro-5-oxa-8,10- diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-13-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-oxetane]-4-yl)-1-piperidyl]methanone; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8,12- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-one; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-12-one; - [4-[3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone; - cis-[4-[4-fluoro-6,8,13-triazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-12-one; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,12- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-one; - [4-(3-fluoro-7-methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone; - [4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4'-tetrahydropyran]-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,4'-tetrahydropyran]-4-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene-4,4'-tetrahydropyran]-12-yl)- 1-piperidyl]methanone; - [4-[4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-7-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - [4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene-4,4'- tetrahydropyran]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene-4,3'- pyrrolidine]-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-5,6,8,9- tetrahydropyrido[2,3-b]indol-7-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-5,6,8,9- tetrahydrospiro[pyrido[2,3-b]indole-7,2'-[1,3]dioxolan]-4-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-3,3'-tetrahydrofuran]-12-yl)- 1-piperidyl]methanone; - [4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-3,3'- tetrahydrofuran]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indol-4-yl)-1-piperidyl]methanone; - [4-(3-fluoro-5,7,8,9-tetrahydrospiro[pyrido[2,3-b]indole-6,2'-[1,3]dioxolan]-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-6-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - [4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene-3,3'- pyrrolidine]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3- yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-5,7,8,9- tetrahydropyrido[2,3-b]indol-6-one; - [4-(3-fluoro-6-methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone; - [4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-azetidine]-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(12-fluoro-4,8,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11-tetraen-13-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-5,7,8,9- tetrahydropyrido[2,3-b]indol-6-one; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(12-fluoro-4-oxa-8,10- diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-13-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[7-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-(7,9-diazatricyclo[6.4.0.02,6]dodeca- 1(12),2(6),8,10-tetraen-12-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(7,9-diazatricyclo[6.4.0.02,6]dodeca- 1(12),2(6),8,10-tetraen-12-yl)-1-piperidyl]methanone; - [4-(7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraen-12-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(12-oxa-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - [4-(7-methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone; - [4-(12-oxa-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one; - trans-[4-[13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14- tetraen-11-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-oxa-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-13-methyl-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-12-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; and - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-6,8- diazatricyclo[7.6.0.02,7]pentadeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone, PAT24007-WO-PCT and the pharmaceutically acceptable salts thereof. In embodiments, the compound is selected from the group consisting of: - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)- 6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - 3-fluoro-N,N-dimethyl-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-cyclobutane]-1'-carboxamide; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-cyclobutane]-1'-carboxylic acid; - methyl 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-11-carboxylate; - methyl 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-12-carboxylate; - [4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol- 4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carboxylic acid; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indole-6-carboxylic acid; - [4-(4'-fluorospiro[1,3-dioxolane-2,12'-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraene]-3'-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[4-fluoro-12-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[4-fluoro-13-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)- 6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol- 4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(4-fluoro-14-oxa-6,8,11-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3- yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(trans)-13-fluoro-6-oxa-15,17-diazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(trans)-15-fluoro-5-oxa-11,13-diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(cis)-15-fluoro-5-oxa-11,13-diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,2'-cyclobutane]-1'-one; PAT24007-WO-PCT - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indole-7-carbonitrile; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indole-5-carbonitrile; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-1'-methyl-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-azetidine]-4-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-hydroxyimino-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-7-carbonitrile; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carbonitrile; - [4-(3-fluoro-1'-methyl-spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-azetidine]-4- yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carboxylic acid; - [4-[4-fluoro-12-(oxetan-3-yl)-6,8,12-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-azetidine]-4-yl)-1-piperidyl]methanone; - [4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[4-fluoro-13-(oxetan-3-yl)-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [4-(12-cyclopropyl-4-fluoro-6,8,12-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indole-5-carboxylic acid; - [4-(13-cyclopropyl-4-fluoro-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-12-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [4-(3-fluoro-6-morpholino-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [4-(4-fluoro-12,12-dioxo-12λ⁶-thia-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(4-fluoro-13,13-dioxo-13λ⁶-thia-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carbonitrile; - [4-[3-fluoro-6-hydroxyimino-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone; - [4-[4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 1-[4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,12- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-12-yl]ethanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - 1-[4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-yl]ethanone; - [4-[4-fluoro-12-(2,2,2-trifluoroethyl)-6,8,12-triazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,1'-cyclobutane]-4-yl)-1-piperidyl]methanone; PAT24007-WO-PCT - [4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,1'-cyclobutane]-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[4-fluoro-13-(2,2,2-trifluoroethyl)-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3- yl]-1-piperidyl]-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carboxylic acid; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-tetrahydrofuran]-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]-2'-one; - [4-[3-fluoro-7-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-7-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(4-fluoro-6,8,12-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(4-fluoro-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]-2'-one; - [4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indole-6-carbonitrile; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; PAT24007-WO-PCT - [4-[(cis)-14-fluoro-4,10,12-triazatetracyclo[7.7.0.02,6.011,16]hexadeca- 1(9),11,13,15-tetraen-15-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-12-one; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carbonitrile; - 1-[13-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-12-fluoro-4,8,10- triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-4-yl]ethanone; - 4-fluoro-11,11-dimethyl-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-12-one; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-15-fluoro-5-oxa-11,13- diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-13-fluoro-6-oxa-15,17- diazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-15-fluoro-5-oxa-11,13- diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone; - [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-[4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [4-[6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-11,11-dimethyl- 6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-14-oxa-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - [4-(4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-(4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,11- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-12-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-tetrahydrofuran]-4-yl)-1-piperidyl]methanone; - [4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-(4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,12- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-11-one; - [4-[3-fluoro-6-hydroxy-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3- yl)-1-piperidyl]-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone; - [4-(4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3- yl)-1-piperidyl]-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - [4-(4-fluoro-6,8,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraen-3- yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone - [4-(14-fluoro-4,10,12-triazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),11,13,15- tetraen-15-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - [4-[6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluoro-6-hydroxy-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(cis)-7-fluoro-3,5-diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8- tetraen-8-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl]-1- piperidyl]methanone; - [4-[12-fluoro-4-(2,2,2-trifluoroethyl)-4,8,10-triazatricyclo[7.4.0.02,7]trideca- 1(13),2(7),9,11-tetraen-13-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3,6,6-trifluoro-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[12-fluoro-4-(2,2,2-trifluoroethyl)-4,8,10- triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11-tetraen-13-yl]-1- piperidyl]methanone; - [4-(12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14- tetraen-11-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(trans)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-11-oxa-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - [4-[(cis)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - [4-[4-fluoro-12-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen- 3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[4-fluoro-13-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen- 3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - 4-fluoro-13-methyl-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one; - [4-(trifluoromethoxy)phenyl]-[4-(3,6,6-trifluoro-5,7,8,9-tetrahydropyrido[2,3-b]indol- 4-yl)-1-piperidyl]methanone; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8,14- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-one; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl)-1- piperidyl]methanone; - [4-(7-fluoro-3,5-diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8- yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[6-(cyclopropylamino)-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - [4-(3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone; - [4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,3'- tetrahydrofuran]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,3'-tetrahydrofuran]-12-yl)- 1-piperidyl]methanone; - [4-[(cis)-4-fluoro-6,8,13-triazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3- yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene-4,3'- pyrrolidine]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-(7-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - [4-(4-fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5,12-pentaen-3-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-(4-fluoro-6,8-diazatricyclo[7.6.0.02,7]pentadeca-1(9),2,4,6-tetraen-3-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-12-carbonitrile; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-13-carbonitrile; - 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-12-carbonitrile; and PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[12-deuterio-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone, and the pharmaceutically acceptable salts thereof. In embodiments where the compound has enantiomeric forms (e.g., where the compound has a chiral centre, such as a chiral carbon atom), the compound is present as a racemic mixture of enantiomers. In embodiments where the compound has a chiral centre (e.g., a chiral carbon atom), the compound is present as the (R) isomer. In other embodiments where the compound has a chiral centre (e.g., a chiral carbon atom), the compound is present as the (S) isomer. Thus, in embodiments the compound is selected from the group consisting of: - (rac)-[4-[3-fluoro-6-(2-fluoroethylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-3-fluoro-6-(2-fluoroethylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-3-fluoro-6-(2-fluoroethylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-trans-[4-[13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-trans-[4-[4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-trans-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - (rac)-2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-7-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone (rac)-[4-[6- (cyclopropylamino)-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-6-(cyclopropylamino)-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-6-(cyclopropylamino)-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - (rac)-[4-(3-fluoro-6-hydroxy-6-methyl-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,3'-tetrahydrofuran]-12-yl]- 1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(4R)-11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,3'-tetrahydrofuran]-12-yl]- 1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(4S)-11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,3'-tetrahydrofuran]-12-yl]- 1-piperidyl]methanone; - (rac)-[4-[11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene- 4,3'-tetrahydrofuran]-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(4R)-11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene- 4,3'-tetrahydrofuran]-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(4S)-11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene- 4,3'-tetrahydrofuran]-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[3-fluoro-6-(2-fluoroethylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-cis-[4-[4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-cis-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - (rac)-[4-[3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-cis-[4-[4-fluoro-6,8,13-triazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(11S, 15S)-4-fluoro-6,8,13-triazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(11R, 15R)-4-fluoro-6,8,13-triazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - (rac)-[4-(3-fluoro-7-methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(12R)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(12S)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-7-methoxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - (rac)-[4-[11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene- 4,3'-pyrrolidine]-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(4R)-11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene- 4,3’-pyrrolidine]-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(4S)-11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene- 4,3'-pyrrolidine]-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-3,3'-tetrahydrofuran]-12-yl)- 1-piperidyl]methanone; - (rac)-[4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene- 3,3'-tetrahydrofuran]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-6-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-6-methoxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - (rac)-[4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene- 3,3'-pyrrolidine]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(3-fluoro-6-methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[7-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7R)-7-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7S)-7-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-[4-(7-methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one; - (6R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one; - (6S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one; - (rac)-trans-[4-[13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(3R, 8R)-13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(3S, 8S)-13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(1R,12S)-7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(1S,12R)-7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl]-1- piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-12-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4-fluoro-12-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; and PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4-fluoro-12-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone, and the pharmaceutically acceptable salts thereof. In embodiments, the compound is selected from the group consisting of: - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(1-hydroxy-1-methyl- ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-(1-hydroxy-1-methyl- ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-(1-hydroxy-1-methyl- ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-3-fluoro-N,N-dimethyl-4-[1-[4-(trifluoromethoxy)benzoyl]-4- piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-cyclobutane]-1'- carboxamide; - (trans)-3-fluoro-N,N-dimethyl-4-[1-[4-(trifluoromethoxy)benzoyl]-4- piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-cyclobutane]-1'- carboxamide; - (cis)-3-fluoro-N,N-dimethyl-4-[1-[4-(trifluoromethoxy)benzoyl]-4- piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-cyclobutane]-1'- carboxamide; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-cyclobutane]-1'-carboxylic acid; - (trans)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-cyclobutane]-1'-carboxylic acid; - (cis)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-cyclobutane]-1'-carboxylic acid; - (rac)-methyl 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-11-carboxylate; - methyl (11R)-3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-11-carboxylate; - (rac)-methyl 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-12-carboxylate; - methyl (12R)-3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-12-carboxylate; - methyl (11S)-3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-11-carboxylate; - methyl (12S)-3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-12-carboxylate; PAT24007-WO-PCT - (rac)-[4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carboxylic acid; - (6R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carboxylic acid; - (6S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carboxylic acid; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-6-carboxylic acid; - (6R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-6-carboxylic acid; - (6S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-6-carboxylic acid; - [4-[(12E / Z)-4-fluoro-12-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(12Z)-4-fluoro-12-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(12E)-4-fluoro-12-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(13E / Z)-4-fluoro-13-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(13Z)-4-fluoro-13-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(13E)-4-fluoro-13-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[(trans)-13-fluoro-6-oxa-15,17-diazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(3R,8S)-13-fluoro-6-oxa-15,17-diazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[(trans)-15-fluoro-5-oxa-11,13-diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - [4-[(2S,7R)-15-fluoro-5-oxa-11,13-diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(2R,7S)-15-fluoro-5-oxa-11,13-diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[(cis)-15-fluoro-5-oxa-11,13-diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(3S,8R)-13-fluoro-6-oxa-15,17-diazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(2S,7S)-15-fluoro-5-oxa-11,13-diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(2R,7R)-15-fluoro-5-oxa-11,13-diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,2'-cyclobutane]-1'-one; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile; - (7R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile; - (7S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-5-carbonitrile; - (5R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-5-carbonitrile; - (5S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-5-carbonitrile; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6E / Z)-3-fluoro-6-hydroxyimino-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6E)-3-fluoro-6-hydroxyimino-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-7-carbonitrile; - (7R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-7-carbonitrile; - (7S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-7-carbonitrile; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carbonitrile; PAT24007-WO-PCT - (5R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carbonitrile; - (5S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carbonitrile; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carboxylic acid; - (5R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carboxylic acid; - (5S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carboxylic acid; - (rac)-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(5R)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-[(5S)-3-fluoro-5- (hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7E / Z)-3-fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7Z)-3-fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7E)-3-fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-5-carboxylic acid; - (7R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-5-carboxylic acid; - (7S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-5-carboxylic acid; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12E / Z)-4-fluoro-12-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12Z)-4-fluoro-12-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12E)-4-fluoro-12-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13E / Z)-4-fluoro-13-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13E)-4-fluoro-13-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13Z)-4-fluoro-13-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - (rac)-[4-(3-fluoro-6-morpholino-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(5R)-3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(5S)-3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6Z)-3-fluoro-6-hydroxyimino-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3S,8S))-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3R,8R)-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7R)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7S)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7R)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7S)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone; - (rac)-[4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carbonitrile; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-(6R)-carbonitrile; - 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-(6S)-carbonitrile; - [4-[(6E / Z)-3-fluoro-6-hydroxyimino-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6Z)-3-fluoro-6-hydroxyimino-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6E)-3-fluoro-6-hydroxyimino-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluoro-(7R)-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[3-fluoro-(7S)-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(12R)-4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - [4-[(12S)-4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-7-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7R)-3-fluoro-7-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7S)-3-fluoro-7-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-[4-[4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone; - [4-[(12R)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone; - [4-[(12S)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carboxylic acid; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluorospiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(4R)-3-fluorospiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(4S)-3-fluorospiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]-2'-one; - (6R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]-2'-one; - (6S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]-2'-one; - (rac)-[4-[3-fluoro-7-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - (rac)-[4-[3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-7-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]-2'-one; - (6R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]-2'-one; - (6S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]-2'-one; - (rac)-[4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-6-carbonitrile; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-[4-[(cis)-14-fluoro-4,10,12-triazatetracyclo[7.7.0.02,6.011,16]hexadeca- 1(9),11,13,15-tetraen-15-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(11R,16R)-14-fluoro-4,10,12-triazatetracyclo[7.7.0.02,6.011,16]hexadeca- 1(9),11,13,15-tetraen-15-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(11S,16S)-14-fluoro-4,10,12-triazatetracyclo[7.7.0.02,6.011,16]hexadeca- 1(9),11,13,15-tetraen-15-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(13R)-4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(13S)-4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carbonitrile; - 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-12-one; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-15-fluoro-5-oxa-11,13- diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7R)-15-fluoro-5-oxa-11,13- diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-13-fluoro-6-oxa-15,17- diazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3S,8S)-13-fluoro-6-oxa-15,17- diazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-15-fluoro-5-oxa-11,13- diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7S)-15-fluoro-5-oxa-11,13- diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7R)-15-fluoro-5-oxa-11,13- diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3R,8R)-13-fluoro-6-oxa-15,17- diazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7S)-15-fluoro-5-oxa-11,13- diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone; - (rac)-[2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-[4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-[(12R)-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; PAT24007-WO-PCT - [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-[(12S)-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; - (rac)-[4-[6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol- 4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol- 4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-(4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-hydroxy-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluorospiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4-yl)-1-piperidyl]methanone; - (rac)-[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-tetrahydrofuran]-4- yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(7E / Z)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(7E)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(7Z)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4-(4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - (rac)-[4-[3-fluoro-6-hydroxy-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3- b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-3-fluoro-6-hydroxy-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3- b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-3-fluoro-6-hydroxy-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol- 4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone; PAT24007-WO-PCT - (rac)-[4-(4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(trans)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11R,15S)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11S,15R)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - (rac)-[4-(4-fluoro-6,8,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(14-fluoro-4,10,12-triazatetracyclo[7.7.0.02,6.011,16]hexadeca- 1(9),11,13,15-tetraen-15-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - (6R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - (6S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - (rac)-[4-[6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol- 4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[3-fluoro-6-hydroxy-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3- b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[(cis)-7-fluoro-3,5-diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8- tetraen-8-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(1R,12R)-7-fluoro-3,5-diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8- tetraen-8-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(1S,12S)-7-fluoro-3,5-diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8- tetraen-8-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(1R,12R)-7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl]-1- piperidyl]methanone; PAT24007-WO-PCT - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(1S,12S)-7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl]-1- piperidyl]methanone; - (rac)-[4-(12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[(trans)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(11R,15S)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(11S,15R)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11R,15R)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - (rac)-[4-[(cis)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(11R,15R)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11S,15S)-4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone; - (rac)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one; - (rac)-[4-[4-fluoro-12-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(12R)-4-fluoro-12-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[((12S)-4-fluoro-12-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[4-fluoro-13-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(13R)-4-fluoro-13-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - [4-[(13S)-4-fluoro-13-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4-fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [4-[(11S,15S)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8-tetraen-8-yl)-1- piperidyl]methanone; - (rac)-[4-(7-fluoro-3,5-diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4,6,8- tetraen-8-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6R)-3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - [4-[(6S)-3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-[6-(cyclopropylamino)-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4- yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone; - (rac)-[4-(3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene- 4,3'-tetrahydrofuran]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene-4,3'-tetrahydrofuran]-12-yl)- 1-piperidyl]methanone; - (rac)-[4-[(cis)-4-fluoro-6,8,13-triazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; - (rac)-[4-(11-fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraene- 4,3'-pyrrolidine]-12-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; PAT24007-WO-PCT - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(7-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - (rac)-4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-12-carbonitrile; - (rac)-3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-13-carbonitrile; - (rac)-3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraene-12-carbonitrile; - (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[12-deuterio-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-12-deuterio-4-fluoro-12-hydroxy- 6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1- piperidyl]methanone; and - [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-12-deuterio-4-fluoro-12-hydroxy- 6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1- piperidyl]methanone, and the pharmaceutically acceptable salts thereof. In embodiments, the compound is selected from the compounds produced in Examples 1 to 294 (i.e., from the group consisting of Compounds 1-294), and the pharmaceutically acceptable salts thereof. In other embodiments, the compound is selected from the compounds obtainable by the synthetic methods described in any one of Examples 1 to 294 (i.e., the methods for synthesising Compounds 1-294), and the pharmaceutically acceptable salts thereof. In embodiments, the compound is selected from the compounds produced in Examples 1 to 90 (i.e., from the group consisting of Compounds 1-90), and the pharmaceutically acceptable salts thereof. In other embodiments, the compound is selected from the compounds obtainable by the synthetic methods described in any one of Examples 1 to 90 (i.e., the methods for synthesising Compounds 1-90), and the pharmaceutically acceptable salts thereof. In embodiments, the compound is selected from the compounds produced in Examples 91 to 294 (i.e., from the group consisting of Compounds 91 to 294), and the pharmaceutically acceptable salts thereof. In other embodiments, the compound is selected from the compounds obtainable by the synthetic methods described in any one of PAT24007-WO-PCT Examples 91 to 294 (i.e., the methods for synthesising Compounds 91 to 294), and the pharmaceutically acceptable salts thereof. In embodiments, the compound is selected from the compounds produced in any one of Examples 8, 9, 14, 29, 30, 44, 59, 67, 68, 79, 81, 83, 85, 86, 87, 90, 91, 111, 122, 125, 126, 136, 137, 139, 144, 145, 146, 147, 149, 150, 154, 155, 156, 159, 160, 161, 168, 171, 172, 173, 183, 184, 185, 191, 192, 204, 210, 222, 227, 228, 233, 240, 245, 288, 289, 293, and 294 (i.e., from the group consisting of Compounds 8, 9, 14, 29, 30, 44, 59, 67, 68, 79, 81, 83, 85, 86, 87, 90, 91, 111, 122, 125, 126, 136, 137, 139, 144, 145, 146, 147, 149, 150, 154, 155, 156, 159, 160, 161, 168, 171, 172, 173, 183, 184, 185, 191, 192, 204, 210, 222, 227, 228, 233, 240, 245, 288, 289, 293, and 294, and the pharmaceutically acceptable salts thereof). In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4- fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4- fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-(12-fluoro-5- oxa-8,10-diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-13-yl)-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-oxetane]-4-yl)-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(12R)-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone salt thereof. PAT24007-WO-PCT In an embodiment, the compound is [4-[(12S)-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone salt thereof. In an embodiment, the compound is (rac)-[4-(4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- piperidyl]-3-fluoro-5,7,8,9-tetrahydropyrido[2,3-b]indol-6-one acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone acceptable salt thereof. PAT24007-WO-PCT In an embodiment, the compound is (6R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- piperidyl]-3-fluoro-spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one F O NH2F F O F acceptable salt thereof. In an embodiment, the compound is (6S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- piperidyl]-3-fluoro-spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one acceptable salt thereof. In an embodiment, the compound is [4-[(3R,8R)-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(3S,8S)-13-fluoro-6,15,17- triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [4-((2S,7S)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-((2R,7R)-12-fluoro-5,14,16- triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12- oxa-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- piperidyl]-4-fluoro-13-methyl-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen- 14-one acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4- fluoro-13-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4- fluoro-13-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. PAT24007-WO-PCT In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-6,8- diazatricyclo[7.6.0.02,7]pentadeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3- fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro- 6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is (7R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile acceptable salt thereof. In an embodiment, the compound is (7S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-1'- methyl-spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-azetidine]-4-yl)-1- piperidyl]methanone acceptable salt thereof. PAT24007-WO-PCT In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6E)-3-fluoro- 6-hydroxyimino-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6Z)-3-fluoro- 6-hydroxyimino-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(5R)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(5S)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone

[0003] PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7E)-3-fluoro- 7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7Z)-3-fluoro- 7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12E)-4- fluoro-12-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12Z)-4- fluoro-12-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13E)-4- fluoro-13-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13Z)-4- fluoro-13-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(5R)-3- fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone

[0004] PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(5S)-3-fluoro- 5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3R,8R)-13- fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3S,8S))-13- fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone F O NH2F F O F acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7R)-12- fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7S)-12- fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7R)-12- fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7S)-12- fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof. In an embodiment, the compound is [4-[(6R)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(6S)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3- fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro- 6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [4-[(12R)-4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(12S)-4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone F O F F O F acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7R)-3- fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7S)-3-fluoro- 7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is 1-[4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- piperidyl]-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-yl]ethanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4- fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone

[0005] PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4- fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4- fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3- yl)-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- fluoro-7-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [4-[(13R)-4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(13S)-4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is 4-fluoro-11,11-dimethyl-3-[1-[4- (trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-14-one PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [4-[(6R)-6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(6S)-6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3- fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone F O NH2F F O F acceptable salt thereof. PAT24007-WO-PCT In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro- 6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone F O NH2F F O F acceptable salt thereof. In an embodiment, the compound is [4-[(7E)-3-fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [4-[(7Z)-3-fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11R,15S)-4- fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11S,15R)-4- fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1- piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is (6R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one acceptable salt thereof. In an embodiment, the compound is (6S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one

[0006] PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4- fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3- yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4- fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3- yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-12- deuterio-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3- yl]-1-piperidyl]methanone acceptable salt thereof. In an embodiment, the compound is [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-12- deuterio-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3- yl]-1-piperidyl]methanone PAT24007-WO-PCT acceptable salt thereof. In embodiments, the compound of the disclosure is characterised according to its inhibitory activity against ERK5, e.g., as measured according to the cell-based assay or cell-free assay described in the examples below. In embodiments, the compound has an IC50value of less than about 10 µM against ERK5 (e.g., when measured according to the cell-free assay described below). In embodiments, the compound has an IC50 value of less than about 5 µM, e.g., less than about 2 µM, 1 µM, 0.5 µM, 0.2 µM, 100 nM, or 50 nM against ERK5 (e.g., when measured according to the cell-free assay described below). In embodiments, the compound has an IC50 value of less than about 10 µM against ERK5 when measured according to the cell-free assay described below. In embodiments, the compound has an IC50value of less than about 5 µM, e.g., less than about 2 µM, 1 µM, 0.5 µM, 0.2 µM, 100 nM, or 50 nM against ERK5 when measured according to the cell-free assay described below. In embodiments, the compound has an IC50value of less than about 10 µM against ERK5 when measured according to the cell-based assay described below. In embodiments, the compound has an IC50 value of less than about 5 µM, e.g., less than about 2 µM, 1 µM, 0.5 µM, 0.2 µM, 100 nM, or 50 nM against ERK5 when measured according to the cell-based assay described below. In embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, PAT24007-WO-PCT 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, and 294. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, and 294. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, and 294. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 97, 98, 99, 100, 101, 102, 103, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 136, 137, 138, 139, PAT24007-WO-PCT 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, and 294. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 73, 75, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 97, 98, 100, 101, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 133, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 166, 167, 168, 169, 170, 171, 172, 173, 175, 177, 178, 179, 181, 182, 183, 184, 185, 186, 188, 189, 190, 191, 192, 193, 194, 195, 196, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, and 294. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 16, 17, 18, 19, 20, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 39, 41, 43, 44, 45, 46, 48, 50, 52, 53, 54, 55, 57, 58, 59, 60, 61, 63, 65, 66, 67, 68, 69, 75, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 97, 98, 100, 101, 107, 108, 109, 110, 111, 112, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 128, 129, 131, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 166, 167, 168, 169, 170, 171, 172, 173, 178, 179, 181, 182, 183, 184, 185, 186, 188, 190, 191, 192, 193, 194, 195, 196, 198, 199, 200, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 222, 223, 224, 225, 226, 227, 228, 230, 231, 232, 233, 234, 236, 238, 239, 240, 241, 242, 243, 245, 246, 247, 249, 250, 252, 253, 254, 255, 256, 257, 258, 260, 262, 263, 264, 266, 267, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, and 294. In other embodiments, the compound is selected from the compound of Examples 2, 3, 4, 5, 7, 8, 9, 13, 14, 16, 17, 18, 20, 23, 24, 25, 28, 29, 30, 31, 32, 33, 35, 38, 39, 41, 43, 44, 46, 50, 52, 53, 54, 55, 57, 58, 59, 61, 63, 65, 66, 67, 68, 69, 75, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 100, 108, 109, 110, 111, 112, 114, 115, 117, 118, 120, PAT24007-WO-PCT 121, 122, 123, 124, 125, 126, 128, 129, 131, 136, 137, 138, 139, 140, 141, 143, 144, 145, 146, 147, 148, 149, 150, 151, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 166, 167, 168, 169, 170, 171, 172, 173, 178, 179, 181, 182, 183, 184, 185, 186, 188, 191, 192, 193, 194, 196, 198, 199, 200, 202, 203, 204, 205, 206, 207, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 223, 225, 226, 227, 228, 230, 232, 233, 234, 239, 240, 241, 242, 243, 245, 249, 250, 252, 254, 257, 258, 260, 262, 267, 269, 271, 272, 273, 274, 275, 276, 277, 278, 282, 286, 287, 288, 289, 290, 291, 292, 293, and 294. In embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 108, 109, 110, 111, 112, 113, 114, 115, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, and 287. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 51, 52, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, 65, 66, 67, 68, 69, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 108, 109, 110, 111, 112, 113, 114, 115, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 249, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, and 287. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, PAT24007-WO-PCT 42, 43, 44, 46, 48, 49, 50, 52, 54, 55, 57, 58, 59, 61, 62, 63, 64, 65, 66, 67, 68, 69, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 108, 109, 110, 111, 112, 113, 114, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 178, 179, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 249, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 280, 281, 282, 283, 284, 285, and 287. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 20, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 46, 48, 49, 50, 52, 54, 55, 57, 58, 59, 61, 62, 63, 64, 65, 66, 67, 68, 69, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 108, 109, 110, 111, 112, 113, 114, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 178, 179, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 249, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 280, 281, 282, 283, 285, and 287. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 20, 23, 24, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 41, 43, 44, 46, 48, 49, 52, 54, 55, 57, 58, 59, 61, 63, 64, 65, 66, 67, 68, 69, 75, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 97, 101, 102, 103, 104, 105, 106, 108, 109, 110, 111, 112, 113, 114, 117, 118, 120, 121, 122, 123, 124, 125, 126, 128, 129, 131, 134, 135, 136, 137, 138, 139, 140, 141, 144, 145, 146, 147, 148, 149, 150, 151, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 170, 171, 172, 173, 178, 181, 182, 183, 184, 185, 186, 188, 191, 192, 193, 194, 195, 196, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 216, 217, 218, 219, 220, 223, 225, 226, 227, 228, 231, 232, 233, 234, 240, 241, 242, 243, 245, 246, 247, 249, 252, 254, 255, 256, 257, 258, 259, 260, 261, 262, 267, 269, 271, 272, 274, 275, 276, 277, 278, 281, 282, 283, 285, and 287. In other embodiments, the compound is selected from the compound of Examples 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 14, 17, 20, 23, 24, 30, 31, 32, 33, 34, 35, 38, 43, 44, 46, 48, 54, 58, 59, 61, 63, 65, 66, 67, 75, 78, 79, 80, 81, 82, 83, 85, 86, 87, and 90, 91, 92, 101, 102, 103, 104, 105, 106, 108, 109, 110, 111, PAT24007-WO-PCT 112, 113, 117, 118, 122, 123, 124, 125, 126, 129, 131, 134, 135, 136, 137, 139, 140, 144, 145, 146, 147, 148, 149, 150, 151, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 164, 165, 166, 167, 168, 170, 171, 172, 173, 181, 183, 184, 185, 186, 188, 191, 192, 193, 194, 196, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 212, 218, 223, 225, 226, 227, 228, 232, 233, 240, 241, 242, 243, 245, 252, 254, 255, 256, 257, 258, 259, 260, 261, 262, 269, 271, 274, 275, 276, 277, 278, 281, 282, 283, 285. In other embodiments, the compound is selected from the compound of Examples 2, 3, 5, 7, 8, 9, 14, 23, 30, 31, 32, 33, 34, 35, 38, 44, 46, 48, 54, 58, 59, 63, 65, 66, and 67, 78, 79, 80, 81, 82, 83, 85, 86, 90, 103, 105, 106, 109, 110, 111, 118, 122, 123, 125, 126, 129, 131, 134, 135, 136, 137, 139, 140, 144, 145, 146, 147, 149, 150, 153, 154, 155, 156, 157, 160, 161, 166, 167, 168, 171, 172, 173, 183, 184, 185, 186, 188, 191, 192, 193, 194, 196, 200, 202, 203, 204, 205, 206, 207, 209, 210, 218, 223, 227, 228, 233, 240, 242, 243, 245, 254, 255, 256, 257, 260, 262, 271, 274, 277, 281, 282, and 283. Processes for producing Compounds of the disclosure and Intermediate Compounds The present disclosure also provides processes for the preparation of compounds as described herein, and intermediates for use in the preparation of said compounds. Accordingly, provided is a process for the preparation of a compound of Formula (I) as defined herein , or a pharmaceutically acceptable salt thereof, wherein the process comprises reacting a compound of Formula HE

[0007] PAT24007-WO-PCT with a compound of Formula J , wherein: Q is either a group R2as defined herein (or a protected version of the same), or taken together with the adjacent carbonyl is an amine protecting group, and wherein ring A, R1, and n are as defined herein, and X is a halogen (e.g. I, Br or Cl). In embodiments, R1is F. In embodiments, the process comprises a chiral separation step (e.g., to isolate one stereoisomer from a mixture of stereoisomers). In embodiments, the process comprises a regioisomer separation step (e.g., to isolate one regioisomer from a mixture of regioisomers). In embodiments, the process comprises a step in which an E (or cis) isomer is separated from a mixture of E and Z isomers. In embodiments, the process comprises a step in which a Z (or trans) isomer is separated from a mixture of E and Z isomers. A person of ordinary skill in the art will be aware of many chiral, stereoisomer, and regioisomer separation methods, for example those illustrated herein. In embodiments, Q is a protected version of a group R2as defined herein. In embodiments, Q is a phenyl group having a protected amine substituent, optionally alongside other substituents (e.g. a group -OCF3). In embodiments, Q is a group R2as defined herein. Accordingly, in embodiments the compound of Formula HE is a compound of Formula H PAT24007-WO-PCT wherein R1, R2, n, and X are as In embodiments, the process of reacting Compound H with Compound J comprises the use of a Pd catalyst. In embodiments, the process comprises the use of a Pd catalyst, a base, and a solvent. A person of ordinary skill in the art will appreciate that references to “a Pd catalyst” include a Pd catalyst / ligand. In embodiments, the Pd catalyst is bis(tri-tert- butylphosphine)palladium (0). In embodiments, the base is 1,4-diazabicyclo[2.2.2]octane. In embodiments, the solvent is DMF. Thus, in embodiments the process comprises the use of bis(tri-tert-butylphosphine)palladium (0) as catalyst, 1,4-diazabicyclo[2.2.2]octane as a base, and DMF a solvent. In embodiments, the process comprises one or more of the steps shown in Scheme 1. In embodiments, the process comprises all of the steps shown in Scheme 1. In embodiments, the process comprises Step 6 of Scheme 1. In embodiments, the process comprises one or more of the steps of Method A. In embodiments, the process is substantially as described in Method A. In embodiments, the process comprises one or more of the steps of Method D. In embodiments, the process is substantially as described in Method D. In embodiments, Q taken together with the adjacent carbonyl is an amine protecting group (e.g., Boc). Accordingly, in embodiments the compound of Formula HE is a compound of Formula E wherein R1, n, and X are as defined herein. PAT24007-WO-PCT In embodiments, the process of reacting Compound E with Compound J comprises the use of a Pd catalyst. In embodiments, the process comprises the use of a Pd catalyst, a base, and a solvent. A person of ordinary skill in the art will appreciate that references to “a Pd catalyst” include a Pd catalyst / ligand. In embodiments, the Pd catalyst is bis(tri-tert- butylphosphine)palladium (0). In embodiments, the base is 1,4-diazabicyclo[2.2.2]octane. In embodiments, the solvent is DMF. Thus, in embodiments the process comprises the use of bis(tri-tert-butylphosphine)palladium (0) as catalyst, 1,4-diazabicyclo[2.2.2]octane as a base, and DMF a solvent. In embodiments, the process comprises one or more of the steps shown in Scheme 3. In embodiments, the process comprises Step 1 of Scheme 3. In embodiments, the process comprises one or more of the steps of Method E. In embodiments, the process is substantially as described in Method E. In another aspect, the disclosure provides a process for the preparation of a compound of Formula (I) as defined herein , or a pharmaceutically acceptable salt thereof, wherein the process comprises the intramolecular cyclisation of a compound of Formula MP , wherein: Q is either a group R2as defined herein (or a protected version of the same), or taken together with the adjacent carbonyl is an amine protecting group; and R3is selected from H and a nitrogen-compatible leaving group (e.g., Ts), PAT24007-WO-PCT and wherein ring A, R1, and n are as defined herein. In embodiments, R3is H. In embodiments, R3is Ts. In embodiments, R1is F. In embodiments, the process comprises a chiral separation step (e.g., to isolate one stereoisomer from a mixture of stereoisomers). In embodiments, the process comprises a regioisomer separation step (e.g., to isolate one regioisomer from a mixture of regioisomers). In embodiments, the process comprises a step in which an E (or cis) isomer is separated from a mixture of E and Z isomers. In embodiments, the process comprises a step in which a Z (or trans) isomer is separated from a mixture of E and Z isomers. A person of ordinary skill in the art will be aware of many chiral, stereoisomer, and regioisomer separation methods, for example those illustrated herein. In embodiments, the intramolecular cyclisation of the compound of Formula MP comprises the use of a hypervalent iodine reagent and optionally a solvent. In embodiments, the hypervalent iodine reagent is PIFA. In embodiments, the solvent is THF. In embodiments, the intramolecular cyclisation of the compound of Formula MP comprises the use of PIFA and THF. In embodiments, Q is a protected version of a group R2as defined herein. In embodiments, Q is a phenyl group having a protected amine substituent, optionally alongside other substituents (e.g. a group -OCF3). In embodiments, Q is a group R2as defined herein. Accordingly, in embodiments the compound of Formula MP is a compound of Formula M1 wherein ring A, R1, R2, R3, and n are as defined herein. In embodiments, R3is H (i.e. the compound is Compound M as defined herein). In other embodiments, R3is Ts (i.e. the compound is Compound M’ as defined herein). In embodiments, the intramolecular cyclisation comprises the use of a silver (I) salt and optionally a solvent. In embodiments, the silver (I) salt is Ag2CO3. In embodiments, the solvent is THF. In embodiments, the intramolecular cyclisation comprises the use of Ag2CO3 and THF. PAT24007-WO-PCT In embodiments, the process comprises one or more of the steps shown in Scheme 2. In embodiments, the process comprises all of the steps shown in Scheme 2. In embodiments, the process comprises Step 2 of Scheme 2. In embodiments, the process comprises one or more of the steps shown in Scheme 2A. In embodiments, the process comprises all of the steps shown in Scheme 2A. In embodiments, the process comprises Step 3 of Scheme 2A. In embodiments, the process comprises one or more of the steps of Method C. In embodiments, the process is substantially as described in Method C. In embodiments, Q taken together with the adjacent carbonyl is an amine protecting group (e.g., Boc). Accordingly, in embodiments the compound of Formula MP is a compound of Formula P1 wherein ring A, R1, R3, and n are as defined herein. In embodiments, R3is H (i.e. the compound is Compound P as defined herein). In other embodiments, R3is Ts (i.e. the compound is Compound P’ as defined herein). In embodiments, the process comprises one or more of the steps shown in Scheme 4. In embodiments, the process comprises all of the steps shown in Scheme 4. In embodiments, the process comprises Step 3 of Scheme 4. In embodiments, the process comprises one or more of the steps of Method F. In embodiments, the process is substantially as described in Method F. In embodiments, the process comprises all of the steps of Method F apart from the steps of N-tosylation and de-tosylation. In embodiments, the compound prepared by the processes defined herein is selected from a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) or Formula (VI) as defined herein, and the pharmaceutically acceptable salts thereof. The present disclosure is also directed to intermediates useful in the preparation of the compounds of the disclosure. A person of ordinary skill in the art will appreciate that the processes described herein in the context of preparing compounds of the disclosure can be used to provide such intermediates. PAT24007-WO-PCT Viewed from this aspect, the disclosure provides a compound of Formula HE or a pharmaceutically acceptable salt thereof, wherein R1and n are as defined herein, and wherein: Q is either a group R2as defined herein (or a protected version of the same), or taken together with the adjacent carbonyl is an amine protecting group (e.g. Boc); and X is a halogen (e.g. I, Br, Cl). In embodiments, R1is F. In embodiments, the compound is a compound of Formula H or a pharmaceutically acceptable salt thereof, wherein R1, R2, n, and X are as defined herein. In other embodiments, the compound is a compound of Formula E PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof, wherein R1, n, and X are as defined herein. The disclosure also provides a compound of Formula MP or a pharmaceutically acceptable salt thereof, wherein ring A, R1, and n are as defined herein, and wherein: Q is either a group R2as defined herein (or a protected version of the same), or taken together with the adjacent carbonyl is an amine protecting group (e.g., Boc); and R3is selected from H and a nitrogen-compatible leaving group (e.g., Ts). In embodiments, R3is H. In other embodiments, R3is Ts. In embodiments, R1is F. In embodiments, the compound is a compound of Formula M1 or a pharmaceutically acceptable ring A, R1, R2,3 R , and n are as defined herein. In embodiments, the compound is a compound of Formula M or Formula M’ , PAT24007-WO-PCT or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and n are as defined herein. In embodiments, the compound is a compound of Formula P1 or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R3, and n are as defined herein. In embodiments, the compound is a compound of Formula P or Formula P’ or a pharmaceutically and n are as defined herein. In embodiments, the compound is selected from: tert-butyl 4-(2-amino-5-fluoro-3-iodo-4- pyridyl)piperidine-1-carboxylate

[0008] PAT24007-WO-PCT [4-(2-amino-5-fluoro-3-iodo-4-pyridyl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone N-[5-fluoro-3-iodo-4-[1-[4-(trifluoromethoxy)benzoyl]-4- piperidyl]-2-pyridyl]-4-methyl-benzenesulfonamide tert-butyl N-[2-[4-(2-amino-5-fluoro-3-iodo-4- pyridyl)piperidine-1-carbonyl]-5- (trifluoromethoxy)phenyl]carbamate tert-butyl 4-[5-fluoro-3-iodo-2-(p-tolylsulfonylamino)-4- pyridyl]piperidine-1-carboxylate tert-butyl N-[2-[4-[5-fluoro-3-iodo-2-(p- tolylsulfonylamino)-4-pyridyl]piperidine-1-carbonyl]-5- (trifluoromethoxy)phenyl]carbamate

[0009] PAT24007-WO-PCT [4-(2-amino-5-fluoro-3-iodo-4-pyridyl)-1-piperidyl]-[4- (pentafluoro-λ⁶-sulfanyl)phenyl]methanone [4-(2-amino-5-fluoro-3-iodo-4-pyridyl)-1-piperidyl]-[2- amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]methanone and the pharmaceutically acceptable salts thereof. It will be appreciated that compounds of the disclosure can act as precursors or intermediates to other compounds of the disclosure. For example, compounds bearing a ketone on ring A may be used as precursors of compounds which carry alkyl groups, hydroxyl groups and / or other groups at the ketone position. The present disclosure thus provides the following compounds which may be useful as intermediates or precursors in the preparation of compounds as disclosed herein: 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]- 5,7,8,9-tetrahydropyrido[2,3-b]indol-6-one 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]- 3-fluoro-5,6,8,9-tetrahydropyrido[2,3-b]indol-7-one

[0010] PAT24007-WO-PCT 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]- 5,6,8,9-tetrahydropyrido[2,3-b]indol-7-one 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]- 3-fluoro-5,7,8,9-tetrahydropyrido[2,3-b]indol-6-one [4-(4-fluoro-6,8,12-triazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(4-fluoro-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]- 4-fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-12-one 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]- 6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen- 12-one PAT24007-WO-PCT 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]- 4-fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-13-one 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]- 6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-13-one [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4'- fluorospiro[1,3-dioxolane-2,12'-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraene]-3'- yl)-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4'- fluorospiro[1,3-dioxolane-2,13'-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraene]-3'- yl)-1-piperidyl]methanone and the pharmaceutically acceptable salts thereof. Pharmaceutical Compositions The present disclosure provides a pharmaceutical composition comprising a compound described herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof), and at least one pharmaceutically acceptable excipient or carrier. In embodiments, the pharmaceutical composition comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical composition comprises a compound of Formula (II) or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical composition comprises a compound of Formula (III) or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical composition PAT24007-WO-PCT comprises a compound of Formula (IV) or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical composition comprises a compound of Formula (V) or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical composition comprises a compound of Formula (VI) or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions of the disclosure may be formulated for administration in solid or liquid form, e.g., using conventional carriers or excipients. Compositions may be adapted for, e.g., oral administration (e.g., as a solution, suspension, tablet, or capsule), parenteral administration (e.g., as a solution, dispersion, suspension, or emulsion, or as a dry powder for reconstitution), or topical application (e.g., as a cream, ointment, patch, or spray to be applied to the skin) using techniques known in the art. Medical Uses Compounds of the present disclosure act as inhibitors of ERK5, which gives them utility in the treatment of ERK5-associated disorders and conditions. In particular, compounds of the disclosure are useful in the treatment of cancers. Viewed from this aspect, the disclosure provides a method of treatment comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof). In a related aspect, the disclosure provides the use of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament. In a further related aspect, the disclosure provides a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) for use in therapy. Compounds of the present disclosure are useful for treating or preventing: diseases or deleterious conditions in which ERK5, or a variant or mutant thereof, is known to play a role; diseases or disorders associated with increased MAPK7 (i.e., ERK5 gene) expression and / or increased ERK5 activity; and diseases or disorders in which inhibition or antagonism of ERK5 activity is beneficial. In one aspect, the present disclosure provides a method of treating or preventing a disease or disorder mediated by ERK5, or a disease or disorder in which ERK5 is implicated, in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof). In a related aspect, the disclosure provides the use of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for the treatment or prevention of a disease or disorder mediated by ERK5, or a disease or disorder in which ERK5 is PAT24007-WO-PCT implicated. In a further related aspect, the disclosure provides a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) for use in the treatment or prevention of a disease or disorder mediated by ERK5, or a disease or disorder in which ERK5 is implicated. In another aspect, the present disclosure provides a method of treating or preventing a disease or disorder associated with ERK5 (e.g., cancer) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof). In a related aspect, the disclosure provides the use of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for the treatment or prevention of a disease or disorder associated with ERK5 (e.g., cancer). In a further related aspect, the disclosure provides a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) for use in the treatment or prevention of a disease or disorder associated with ERK5 (e.g., cancer). In another aspect, the present disclosure provides a method of treating or preventing cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof). In a related aspect, the disclosure provides the use of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for the treatment or prevention of cancer. In a further related aspect, the disclosure provides a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) for use in the treatment or prevention of cancer. In embodiments, the compound reduces angiogenesis, reduces or prevents metastasis, reduces inflammation, blocks tumorigenesis (e.g., in part or completely), reduces evasion of growth suppression, reduces or inhibits growth of cancerous or pre-cancerous cells, supresses proliferation of cancerous or pre-cancerous cells, and / or reduces the survival of cancerous or pre-cancerous cells. In embodiments, the cancer is characterized by increased MAPK7 (i.e., ERK5 gene) expression and / or increased ERK5 activity. In embodiments, the cancer has elevated ERK5 activity. In embodiments, the cancer overexpresses ERK5. In embodiments, the cancer is characterised by MAPK7 genomic amplification and / or constitutively active ERK5 signalling. In embodiments, the cancer has genomically amplified ERK5. In embodiments, the cancer has constitutively active ERK5 signalling. PAT24007-WO-PCT In embodiments, the cancer is a solid tumour (e.g., a melanoma, carcinoma, or blastoma). In other embodiments, the cancer is leukaemia (e.g., chronic lymphocytic leukaemia, CLL; acute myelogenous leukaemia, AML; or chronic myelogenous leukaemia, CML). In embodiments, the cancer is a primary tumour. In other embodiments, the cancer is a secondary tumour (e.g., a metastatic tumour). In embodiments, the cancer is selected from breast cancer (e.g., ductal breast carcinoma, or breast adenocarcinoma), liver cancer, kidney cancer (e.g., hepatocellular carcinoma), prostate cancer, colorectal cancer (CRC), lung cancer (e.g., non-small cell lung cancer, NSCLC; lung adenocarcinoma; or lung squamous cell carcinoma), pancreatic cancer (e.g., adenocarcinoma), ovarian cancer, brain cancer (e.g., glioblastoma), cervical cancer (e.g., adenocarcinoma), gastric cancer, skin cancer (e.g., melanoma), bile duct cancer (e.g., cholangiocarcinoma), nervous system cancer (e.g., neuroblastoma), and melanoma. In embodiments, the cancer is selected from leukaemia (e.g., acute leukaemia, acute lymphocytic leukaemia, acute myelocytic leukaemia, acute myeloblastic leukaemia, acute promyelocytic leukaemia, acute myelomonocytic leukaemia, acute monocytic leukaemia, acute erythroleukemia, chronic leukaemia, chronic myelocytic leukaemia, or chronic lymphocytic leukaemia), polycythaemia vera, lymphoma (e.g., Hodgkin's disease or non- Hodgkin's disease), Waldenström macroglobulinemia, and multiple myeloma. In embodiments, the cancer is selected from leukaemia (e.g., chronic myeloid leukaemia), breast cancer, multiple myeloma, colon cancer, colorectal cancer, lung cancer, pancreatic cancer, renal cell carcinoma, mesothelioma, adenocarcinoma, neuroblastoma, melanoma, and hepatocellular carcinoma. In another aspect, the disclosure provides a method of inhibiting ERK5 activity, the method comprising contacting ERK5 (e.g., a cell comprising ERK5) with a compound of the present disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof). In embodiments, the method is an in vitro or ex vivo method. In other embodiments the method is an in vivo method. In a related aspect, the disclosure provides an in vitro method of inhibiting ERK5 activity in a cell, the method comprising contacting the cell with a compound of the present disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof). Compounds of the present disclosure (e.g., compounds of Formula (I)) and the pharmaceutically acceptable salts thereof may be administered as pharmaceutical compositions, which may optionally comprise one or more pharmaceutically acceptable excipients. PAT24007-WO-PCT It will be appreciated that the methods and treatments of the various aspects of this disclosure may be effected by administering to a subject an effective amount of a compound of the disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof), in the form of a pharmaceutical composition, which may optionally comprise one or more pharmaceutically acceptable excipients, as described herein. The compounds of the disclosure may be used alone (e.g., as a monotherapy) or in combination with one or more cancer therapies. Having been generally described herein, the follow non-limiting examples are provided to further illustrate this disclosure. EXAMPLES General synthetic schemes The following scheme, Scheme 1, illustrates an exemplary way of preparing compounds in accordance with the present disclosure and examples (e.g. compounds of Formula (I)): According to Scheme 1 (in which ring A, R1, R2, and n may be, e.g., as described above), Compound C can be obtained in STEP 1 by Suzuki coupling between Compound A and Compound B (in which -B(OR)2is a boronate group such as -B(Pin)) using a palladium catalyst such as PdCl2(dppf).CH2Cl2in the presence of a base such as potassium phosphate PAT24007-WO-PCT tribasic. Compound C can be reduced in STEP 2 to Compound D by hydrogenation with a catalyst such as Pd / C under hydrogen pressure (H2) around 5 bars at 40 °C, for example. Compound D can then be converted to Compound E (in which X may be I, Br, or Cl) in STEP 3 by halogenation with NIS, NBS, or NCS (i.e. X = I, Br, or Cl) for example. Compound E can be N-deprotected in STEP 4 by using HCl or TFA to give Compound F. Compound H can then be prepared in STEP 5 by reaction of Compound F with carboxylic acid Compound G, using conditions known by the person skilled in the art such as TBTU in a solvent like DMF in presence of a base such as DIPEA. Compound H, in the presence of Compound J, can be then converted into Compound K in STEP 6 using a palladium catalyst such as Pd(t-Bu3P)2 in the presence of a base such as DABCO. The following scheme, Scheme 2, illustrates an alternative way of preparing Compound K from Compound H: According to Scheme 2 (in which ring A, R1, R2, and n may be, e.g., as described above), Compound M can be obtained by Suzuki coupling between Compound H (in which X may be I, Br, or Cl) and Compound L (in which -B(OR)2 is a boronate group such as -B(Pin)) in STEP 1 using a palladium catalyst such as PdCl2(dppf).CH2Cl2 in the presence of a base such as potassium carbonate, for example. Compound K can then be obtained directly from Compound M in the in the presence of a hypervalent iodine(III) reagent such as PIFA in STEP 2. In some cases, Compound K can be prepared from Compound H via N-protected compounds according to the following scheme, Scheme 2A:

[0011] PAT24007-WO-PCT According to Scheme 2A (in which ring A, R1, R2, and n may be, e.g., as described above), Compound H’ (in which X may be I, Br, or Cl) can be obtained in STEP 1 by tosylation of Compound H with tosyl chloride using a base such as sodium hydride, for example. Compound H’ can then be transformed, in the presence of Compound L (in which -B(OR)2 is a boronate group such as -B(Pin)), into Compound M’ in STEP 2 by Suzuki coupling using a palladium catalyst such as PdCl2(dppf).CH2Cl2 in the presence of a base such as potassium carbonate, for example. Compound K’ can be obtained in STEP 3 from Compound M’ in the presence of a hypervalent iodine(III) reagent such as PIFA. Compound K’ can be N- deprotected in STEP 4 by using sodium hydroxide in EtOH for example, to give Compound K. The following scheme, Scheme 3, illustrates an alternative way of preparing Compound K from Compound E:

[0012] PAT24007-WO-PCT Compound N can be obtained from Compound E (in which X may be I, Br, or Cl) in STEP 1 in the presence of Compound J, using a palladium catalyst such as Pd(t-Bu3P)2 in the presence of a base such as DABCO. Compound N can be N-deprotected in STEP 2, by using HCl or TFA to give Compound O. Compound K can then be prepared from Compound O in STEP 3 with carboxylic acid Compound G, using conditions known by the person skilled in the art such as TATU in a solvent like DMF in presence of a base such as DIPEA. The following scheme, Scheme 4, illustrates an alternative way of preparing Compound N from Compound E: SCHEME 4 According to Scheme 4 (in which ring A, R1, and n may be, e.g., as described above), Compound E’ can be obtained in STEP 1 by tosylation of Compound E (in which X may be I, Br, or Cl) with tosyl chloride using a base such as sodium hydride, for example. Compound E’ can then be transformed into Compound P’, by Suzuki coupling with Compound L using a PAT24007-WO-PCT palladium catalyst such as PdCl2(dppf).CH2Cl2 in the presence of a base such as potassium carbonate, for example. Compound N’ can be obtained in STEP 3 from Compound P’ in the presence of a hypervalent iodine(III) reagent such as PIFA. Compound N’ can be N- detosylated in STEP 4 by using sodium hydroxide in EtOH for example, to give Compound N. The following scheme, Scheme 5, illustrates a further exemplary way of preparing Compound K via Compound N: According to Scheme 5 (in which ring A, R1, R2, and n may be, e.g., as described above), Compound R can be obtained in STEP 1 by acylation of Compound Q in the presence of a base such as LDA. Compound R can be transformed in STEP 2 to Compound S by reduction with a hydride source such as DIBAL-H, for example. Compound S can then be converted to Compound T in STEP 3 by reaction with PBr3. Compound U can be obtained in STEP 4 from Compound T in the presence of triethylphosphite. Compound U is transformed in STEP 5 to Compound W in the presence of Compound V (in which ring A’ is a precursor to ring A, e.g. having one fewer ring carbon atoms than ring A) and a base such as potassium tert-butoxide. Nucleophilic aromatic substitution of Compound W with sodium azide gives Compound X in PAT24007-WO-PCT STEP 6. Compound X is then transformed into Compound Y in the presence of an iron catalyst and zinc powder in STEP 7; during STEP 7, ring A’ in Compound X undergoes rearrangement to furnish ring A in Compound Y. Suzuki coupling reaction of Compound Y with Compound B (in which -B(OR)2 is a boronate group such as -B(Pin)) in STEP 8, using a palladium catalyst such as PdCl2(dppf).CH2Cl2in the presence of a base such as sodium carbonate, furnishes Compound Z. Compound Z can be reduced in STEP 9 to Compound N by hydrogenation with a catalyst such as Pd / C under hydrogen pressure (H2) around 1 bar, for example. Compound N can be N-deprotected in STEP 10 using HCl or TFA to give Compound O. Compound K can then be prepared from Compound O in STEP 11 by reaction with carboxylic acid Compound G, using conditions known by the person skilled in the art such as EDCI and HOBt in a solvent like DMF in presence of a base such as DIPEA. The following scheme, Scheme 6, illustrates an alternative way of preparing Compound N: SCHEME 6 According to Scheme 6 (in which ring A, R1, and n may be, e.g., as described above), Compound AB can be obtained in STEP 1 by condensation of Compound AA with p- toluenesulfonyl hydrazide. Compound P can be obtained in STEP 2 by Barluenga-Valdés cross coupling reaction with Compound E (in which X may be I, Br, or Cl) and Compound AB, using a palladium catalyst such as Pd(OAc)2and phosphonium ligand such as tri-tert- butylphosphonium tetrafluoroborate in the presence of a base such as potassium carbonate. Compound N can be obtained in STEP 3 from Compound P in the presence of a hypervalent iodine(III) reagent such as PIFA. The following scheme, Scheme 7, illustrates an alternative way of preparing Compound Z: PAT24007-WO-PCT SCHEME 7 According to Scheme 7 (in which ring A, R1, and n may be, e.g., as described above), Compound AD can be obtained in STEP 1 by Suzuki coupling reaction of Compound AC with Compound L, using a palladium catalyst such as PdCl2(dppf) in the presence of a base such as sodium carbonate. Nucleophilic aromatic substitution reaction of Compound AD with sodium azide gives Compound AE in STEP 2. Compound AE is then transformed into Compound AF in the presence of an iridium catalyst and AgSbF6in STEP 3. Compound Z can be obtained in STEP 4 by Suzuki coupling reaction of Compound AF with Compound B (in which -B(OR)2 is a boronate group such as -B(Pin)), using a palladium catalyst such as Pd(t-Bu3P)2 in the presence of a base such as potassium carbonate tribasic. The following scheme, Scheme 8, illustrates an alternative way of preparing Compound Z: SCHEME 8 According to Scheme 8 (in which ring A, R1, and n may be, e.g., as described above), Compound AF can be obtained in STEP 1 from Compound AG (in which X may be I, Br, or Cl) and Compound J, using a palladium catalyst such as Pd(Pt-Bu3)2 in the presence of a base PAT24007-WO-PCT such as DABCO. Compound AF can then be transformed in STEP 2, in the presence of Compound B (in which -B(OR)2 is a boronate group such as -B(Pin)), into Compound Z by Suzuki coupling using a palladium catalyst such as PdCl2(dppf).CH2Cl2 in the presence of a base such as cesium carbonate, for example. Where necessary in the aforementioned transformations, protecting groups may be used, e.g., on free -NH2 substituents of R2or of ring A. Suitable protection strategies will be apparent to a person of skill in the art in view of the present disclosure. For example, compounds of the disclosure (e.g., compounds of Formula (I)) in which R2is -(C6-C10)aryl substituted with -NH2, can be prepared from the corresponding -NHBOC compound, which can be prepared by a method analogous to the above schemes and N-deprotected using conditions described herein or otherwise known to the skilled person. Compounds of the disclosure (e.g., compounds of Formula (I)) in which ring A is a heterocycloalkane comprising at least one nitrogen ring atom can be prepared from the corresponding N-protected (e.g. NBOC) compound, which can be N-deprotected. Compounds in which ring A is substituted with -OH or -NH2, can be prepared from the corresponding O-protected or N-protected compound, which can be prepared by methods analogous to the above schemes and O-deprotected or N- deprotected using conditions described herein or otherwise known to the skilled person. Compounds in which ring A is substituted with oxo (e.g. rings comprising a carbonyl, i.e. -(C=O), group) can be prepared from a corresponding acetal compound (e.g. -(O- CH2CH2-O)-), which can be prepared by a method analogous to the above schemes and revealed by exposure to, e.g., acidic reaction conditions. Certain compounds of the disclosure may carry substituents which are capable of undergoing further transformation to prepare additional compounds in accordance with the disclosure (e.g. compounds of Formula (I)). For example, compounds obtainable, e.g., according to the above schemes (such as, e.g., Compound K) in which ring A is substituted with oxo (e.g. rings comprising a carbonyl, i.e. -(C=O)-, group), can be submitted to chemical transformations such as: (1) nucleophilic addition; (2) reductive amination; and (3) reduction with hydride reagents; to give the corresponding compounds of the disclosure (e.g. compounds of Formula (I)) in which, e.g.: (1) ring A is substituted with -OH, and a further substituent (e.g. selected from -(C1-C3)alkyl optionally substituted with one or more halo or -OH, -(C3-C6)cycloalkyl, 3- to 6-membered heterocycloalkyl, -O(C1-C3)alkyl and -CN); (2) ring A is substituted with -NHR’, in which R’ may be, e.g., as described above; and (3) ring A is substituted with -OH. Compounds which possess one or more stereogenic centers can be purified, e.g. using chiral separation techniques such as chiral HPLC or SFC, to obtain separate isomers. PAT24007-WO-PCT Experimental techniques1H NMR Spectra at 400 and 500 MHz were performed on a Bruker Avance DRX-400 and Bruker Avance DPX-500 spectrometer, respectively, with the chemical shifts (δ in ppm) in the solvent dimethyl sulfoxide-d6 (DMSO-d6) referenced at 2.5 ppm at the quoted temperatures. Coupling constants (J) are given in Hertz. The liquid chromatography / mass spectra (LC / MS) were obtained on a UPLC Acquity Waters instrument, light scattering detector Sedere and SQD Waters mass spectrometer using UV detection DAD 210<l<400 nm and column Acquity UPLC CSH C181.7 µm, dimension 2.1x50 mm, mobile phase H2O + 0.1% HCO2H / CH3CN + 0.1% HCO2H. All synthetic reactions were performed under an inert atmosphere, unless otherwise stated. In the following examples, when the source of the starting products is not specified, it should be understood that said products are known compounds (e.g., commercially available compounds from suppliers such as Sigma-Aldrich). Examples 1 to 294 – Compounds Tables 1a and 1b below list specific compounds of the present disclosure along with their name and structure (Table 1a), as well as their methods of preparation and characterization by NMR and LC / MS (Table 1b). Table 1a: Example No.Structure Name[4-[3-fluoro-6-(2-fluoroethylamino)-6,7,8,9- 1 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluoro-6-(2-fluoroethylamino)-6,7,8,9- 2 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name(rac)-[4-(3-fluoro-7-hydroxy-6,7,8,9-tetrahydro- 3 5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- 4 piperidyl]-6,8,14- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-13-one (rac)-trans-[4-[13-fluoro-6,15,17- 5 triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-trans-[4-[4-fluoro-13-oxa-6,8- 6 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-trans-[2-amino-4- 7 (trifluoromethoxy)phenyl]-[4-[4-fluoro-13-oxa- 6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 8 fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 9 fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 [4-[6-(cyclopropylamino)-3-fluoro-6,7,8,9- 10 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[6-(cyclopropylamino)-3-fluoro-6,7,8,9- 11 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [4-(11-fluorospiro[7,9- 12 diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11- tetraene-4,4'-piperidine]-12-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- 13 b]indole-6,3'-oxetane]-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 14 (3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone PAT24007-WO-PCT Example No.Structure Name[4-(3-fluoro-5,6,8,9-tetrahydrospiro[pyrido[2,3- 15 b]indole-7,2'-dioxolan]-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 16 piperidyl]-5,6,8,9-tetrahydropyrido[2,3-b]indol- 7-one (rac)-[4-(3-fluoro-6-hydroxy-6-methyl-5,7,8,9- 17 tetrahydropyrido[2,3-b]indol-4-yl)-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[11- 18 fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca- 1(8),2(6),9,11-tetraene-4,3'-tetrahydrofuran]-12- yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[11- 19 fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca- 1(8),2(6),9,11-tetraene-4,3'-tetrahydrofuran]-12- yl]-1-piperidyl]methanone, Isomer 2 1-[12-fluoro-13-[1-[4- 20 (trifluoromethoxy)benzoyl]-4-piperidyl]-4,8,10- triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12- tetraen-4-yl]ethanone PAT24007-WO-PCT Example No.Structure Name[4-[11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11- 21 tetraene-4,3'-tetrahydrofuran]-12-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11- 22 tetraene-4,3'-tetrahydrofuran]-12-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 (rac)-[4-[3-fluoro-6-(2-fluoroethylamino)- 23 6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[4-[3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9- 24 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(12- 25 fluoro-3-oxa-8,10- diazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11- tetraen-13-yl)-1-piperidyl]methanone [4-(12-fluoro-3-oxa-8,10- 26 diazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11- tetraen-13-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name(rac)-cis-[4-[4-fluoro-13-oxa-6,8- 27 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-cis-[2-amino-4-(trifluoromethoxy)phenyl]- 28 [4-[4-fluoro-13-oxa-6,8- diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(12- 29 fluoro-5-oxa-8,10- diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12- tetraen-13-yl)-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- 30 fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-oxetane]-4-yl)-1- piperidyl]methanone 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 31 piperidyl]-4-fluoro-6,8,12- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-13-one 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 32 piperidyl]-4-fluoro-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-12-one PAT24007-WO-PCT Example No.Structure Name[4-[3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H- 33 pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H- 34 pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 cis-[4-[4-fluoro-6,8,13- 35 triazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 cis-[4-[4-fluoro-6,8,13- 36 triazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- 37 piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-12-one 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- 38 piperidyl]-6,8,12- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-13-one PAT24007-WO-PCT Example No.Structure Name(rac)-[4-(3-fluoro-7-methoxy-6,7,8,9-tetrahydro- 39 5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- 40 b]indole-6,4'-tetrahydropyran]-4-yl)-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- 41 fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,4'-tetrahydropyran]-4-yl)-1- piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(11- 42 fluorospiro[7,9-diazatricyclo[6.4.0.02,6]dodeca- 1(12),2(6),8,10-tetraene-4,4'-tetrahydropyran]- 12-yl)-1-piperidyl]methanone [4-[4-fluoro-12-hydroxy-6,8- 43 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[4-fluoro-12-hydroxy-6,8- 44 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 45 (3-fluoro-7-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 46 (4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]methanone [4-(11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10- 47 tetraene-4,4'-tetrahydropyran]-12-yl)-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-[11-fluorospiro[7,9- 48 diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10- tetraene-4,3'-pyrrolidine]-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[11-fluorospiro[7,9- 49 diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10- tetraene-4,3'-pyrrolidine]-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 50 piperidyl]-3-fluoro-5,6,8,9-tetrahydropyrido[2,3- b]indol-7-one PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- 51 fluoro-5,6,8,9-tetrahydrospiro[pyrido[2,3- b]indole-7,2'-[1,3]dioxolan]-4-yl)-1- piperidyl]methanone (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- (11-fluorospiro[7,9- 52 diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11- tetraene-3,3'-tetrahydrofuran]-12-yl)-1- piperidyl]methanone (rac)-[4-(11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11- 53 tetraene-3,3'-tetrahydrofuran]-12-yl)-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 54 (3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- 55 fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol- 4-yl)-1-piperidyl]methanone [4-(3-fluoro-5,7,8,9-tetrahydrospiro[pyrido[2,3- 56 b]indole-6,2'-[1,3]dioxolan]-4-yl)-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 57 (3-fluoro-6-methoxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone (rac)-[4-(11-fluorospiro[7,9- 58 diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10- tetraene-3,3’-pyrrolidine]-12-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[4-(4-fluoro-13-hydroxy-6,8- 59 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3- 60 b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 61 piperidyl]-5,7,8,9-tetrahydropyrido[2,3-b]indol- 6-one (rac)-[4-(3-fluoro-6-methoxy-6,7,8,9-tetrahydro- 62 5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- 63 b]indole-6,3’-azetidine]-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(12-fluoro-4,8,10- triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11- 64 tetraen-13-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, hydrochloride 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- 65 piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-14-one 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 66 piperidyl]-4-fluoro-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-14-one 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 67 piperidyl]-3-fluoro-5,7,8,9-tetrahydropyrido[2,3- b]indol-6-one [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4- 68 fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-3-yl)-1- piperidyl]methanone PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-(12- 69 fluoro-4-oxa-8,10- diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12- tetraen-13-yl)-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[7- 70 methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indol-4-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[7- 71 methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indol-4-yl]-1-piperidyl]methanone, Isomer 2 [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4- 72 (7,9-diazatricyclo[6.4.0.02,6]dodeca- 1(12),2(6),8,10-tetraen-12-yl)-1- piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(7,9- 73 diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10- tetraen-12-yl)-1-piperidyl]methanone [4-(7,9-diazatricyclo[6.4.0.02,6]dodeca- 74 1(12),2(6),8,10-tetraen-12-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-(12- 75 oxa-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone (rac)-[4-(7-methoxy-6,7,8,9-tetrahydro-5H- 76 pyrido[2,3-b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(12-oxa-6,8- 77 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 78 piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]- 2’-one, Isomer 1 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 79 piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]- 2'-one, Isomer 2 trans-[4-[13-fluoro-6,15,17- 80 triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Nametrans-[4-[13-fluoro-6,15,17- 81 triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [4-(12-fluoro-5,14,16- 82 triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-(12-fluoro-5,14,16- 83 triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[7- fluoro-3,5- 84 diazatetracyclo[10.2.1.02,10.04,9]pentadeca- 2(10),4,6,8-tetraen-8-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4- 85 fluoro-12-oxa-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]methanone 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 86 piperidyl]-4-fluoro-13-methyl-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-14-one PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 87 fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 88 fluoro-12-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 89 fluoro-12-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4- 90 fluoro-6,8-diazatricyclo[7.6.0.02,7]pentadeca- 1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 91 fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 92 fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name3-fluoro-N,N-dimethyl-4-[1-[4- (trifluoromethoxy)benzoyl]-4- 93 piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-cyclobutane]-1'-carboxamide, Isomer 1 3-fluoro-N,N-dimethyl-4-[1-[4- (trifluoromethoxy)benzoyl]-4- 94 piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-cyclobutane]-1'-carboxamide, Isomer 2 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 95 piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-cyclobutane]-1'-carboxylic acid, Isomer 1 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 96 piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-cyclobutane]-1'-carboxylic acid, Isomer 2 methyl 3-[1-[2-amino-4- 97 (trifluoromethoxy)benzoyl]-4-piperidyl]-4- fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraene-11-carboxylate, Isomer 1 PAT24007-WO-PCT Example No.Structure Namemethyl 3-[1-[2-amino-4- 98 (trifluoromethoxy)benzoyl]-4-piperidyl]-4- fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraene-12-carboxylate, Isomer 1 methyl 3-[1-[2-amino-4- (trifluoromethoxy)benzoyl]-4-piperidyl]-4- 99 fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraene-11-carboxylate, Isomer 2 methyl 3-[1-[2-amino-4- 100 (trifluoromethoxy)benzoyl]-4-piperidyl]-4- fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraene-12-carboxylate, Isomer 2 [4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)- 101 6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)- 102 6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 103 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-6-carboxylic acid, Isomer 1 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 104 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-6-carboxylic acid, Isomer 2 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 105 piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carboxylic acid, Isomer 1 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 106 piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-6-carboxylic acid, Isomer 2 [4-(4'-fluorospiro[1,3-dioxolane-2,12'-6,8- 107 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraene]-3'-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name[4-[4-fluoro-12-hydroxyimino-6,8- 108 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[4-fluoro-12-hydroxyimino-6,8- 109 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [4-[4-fluoro-13-hydroxyimino-6,8- 110 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 111 [3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone (rac)-[4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)- 112 6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]- 1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name[4-(4-fluoro-14-oxa-6,8,11- 113 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-[(trans)-13-fluoro-6-oxa-15,17- 114 diazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[(trans)-15-fluoro-5-oxa-11,13- 115 diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[(trans)-15-fluoro-5-oxa-11,13- 116 diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [4-[(cis)-15-fluoro-5-oxa-11,13- 117 diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Name[4-[(trans)-13-fluoro-6-oxa-15,17- 118 diazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [4-[(cis)-15-fluoro-5-oxa-11,13- 119 diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 (rac)-4-[1-[2-amino-4- 120 (trifluoromethoxy)benzoyl]-4-piperidyl]-3- fluoro-spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,2'-cyclobutane]-1'-one 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 121 piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-7-carbonitrile, Isomer 1 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 122 piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-7-carbonitrile, Isomer 2 PAT24007-WO-PCT Example No.Structure Name4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 123 piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carbonitrile, Isomer 1 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 124 piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carbonitrile, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- 125 fluoro-1'-methyl-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-azetidine]-4- yl)-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 126 fluoro-6-hydroxyimino-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 1 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 127 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-7-carbonitrile, Isomer 1 PAT24007-WO-PCT Example No.Structure Name3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 128 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-7-carbonitrile, Isomer 2 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 129 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-5-carbonitrile, Isomer 1 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 130 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-5-carbonitrile, Isomer 2 [4-(3-fluoro-1'-methyl-spiro[5,7,8,9- 131 tetrahydropyrido[2,3-b]indole-6,3'-azetidine]-4- yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 132 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-5-carboxylic acid, Isomer 1 PAT24007-WO-PCT Example No.Structure Name3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 133 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-5-carboxylic acid, Isomer 2 [4-[4-fluoro-12-(oxetan-3-yl)-6,8,12- 134 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- 135 fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-azetidine]-4-yl)-1- piperidyl]methanone [4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9- 136 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9- 137 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name[4-[4-fluoro-13-(oxetan-3-yl)-6,8,13- 138 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 139 fluoro-7-hydroxyimino-5,6,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 1 [4-(12-cyclopropyl-4-fluoro-6,8,12- 140 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 141 piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carboxylic acid, Isomer 1 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 142 piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indole-5-carboxylic acid, Isomer 2 PAT24007-WO-PCT Example No.Structure Name[4-(13-cyclopropyl-4-fluoro-6,8,13- 143 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 144 fluoro-12-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 145 fluoro-12-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 146 fluoro-13-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1

[0013] PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 147 fluoro-13-hydroxyimino-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 (rac)-[4-(3-fluoro-6-morpholino-6,7,8,9- 148 tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 149 fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 150 fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 151 fluoro-6-hydroxyimino-5,7,8,9- tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name[4-(4-fluoro-12,12-dioxo-12λ⁶-thia-6,8- 152 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(4-fluoro-13,13-dioxo-13λ⁶-thia-6,8- 153 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4- [(trans)-13-fluoro-6,15,17- 154 triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4- [(trans)-13-fluoro-6,15,17- 155 triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[12- fluoro-5,14,16- 156 triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[12- fluoro-5,14,16- 157 triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl]-1- piperidyl]methanone, Isomer 2 [4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9- 158 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9- 159 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 160 fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 161 fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 162 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-6-carbonitrile, Isomer 1 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 163 piperidyl]-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-6-carbonitrile, Isomer 2 [4-[3-fluoro-6-hydroxyimino-5,7,8,9- 164 tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluoro-6-hydroxyimino-5,7,8,9- 165 tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone, Isomer 2 [4-[3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H- 166 pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure NameF O F F O N [4-[3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H- 167 pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4- HO F(trifluoromethoxy)phenyl]methanone, Isomer 2 N Isomer 2HN[4-[4-fluoro-12-hydroxy-12-methyl-6,8- 168 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[4-fluoro-12-hydroxy-12-methyl-6,8- 169 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 1-[4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]- 170 4-piperidyl]-6,8,12- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-12-yl]ethanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 171 fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 172 fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone, Isomer 2 1-[4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]- 173 4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-13-yl]ethanone [4-[4-fluoro-12-(2,2,2-trifluoroethyl)-6,8,12- 174 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-(3- 175 fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,1'-cyclobutane]-4-yl)-1- piperidyl]methanone [4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- 176 b]indole-6,1'-cyclobutane]-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name[4-[4-fluoro-13-(2,2,2-trifluoroethyl)-6,8,13- 177 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-[4-fluoro-12-hydroxy-6,8- 178 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(pentafluoro-λ⁶- sulfanyl)phenyl]methanone, Isomer 1 [4-[4-fluoro-12-hydroxy-6,8- 179 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4-(pentafluoro-λ⁶- sulfanyl)phenyl]methanone, Isomer 2 (rac)-3-fluoro-4-[1-[4- 180 (trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-5-carboxylic acid [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 181 fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-tetrahydrofuran]-4-yl]-1- piperidyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 182 fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-tetrahydrofuran]-4-yl]-1- piperidyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 183 fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 184 fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 185 (4-fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]methanone 4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 186 piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]- 2'-one, Isomer 1 PAT24007-WO-PCT Example No.Structure Name4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 187 piperidyl]-3-fluoro-spiro[5,7,8,9- tetrahydropyrido[2,3-b]indole-6,3'-pyrrolidine]- 2'-one, Isomer 2 (rac)-[4-[3-fluoro-7-(hydroxymethyl)-6,7,8,9- 188 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-[3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- 189 b]indole-6,3'-tetrahydrofuran]-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- 190 b]indole-6,3'-tetrahydrofuran]-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 191 [3-fluoro-7-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone PAT24007-WO-PCT Example No.Structure Name(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 192 [3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone (rac)-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9- 193 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(4-fluoro-6,8,12- 194 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(4-fluoro-6,8,13- 195 triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 196 piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-pyrrolidine]-2'-one, Isomer 1 PAT24007-WO-PCT Example No.Structure Name3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 197 piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-pyrrolidine]-2'-one, Isomer 2 (rac)-[4-[3-fluoro-6-(hydroxymethyl)-6,7,8,9- 198 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-4-[1-[2-amino-4- 199 (trifluoromethoxy)benzoyl]-4-piperidyl]-3- fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indole-6-carbonitrile (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 200 [3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro- 5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]methanone [4-[(cis)-14-fluoro-4,10,12- 201 triazatetracyclo[7.7.0.02,6.011,16]hexadeca- 1(9),11,13,15-tetraen-15-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Name[4-[(cis)-14-fluoro-4,10,12- 202 triazatetracyclo[7.7.0.02,6.011,16]hexadeca- 1(9),11,13,15-tetraen-15-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [4-[4-fluoro-13-hydroxy-6,8- 203 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[4-fluoro-13-hydroxy-6,8- 204 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- (12-fluoro-5,14,16- 205 triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl)-1- piperidyl]methanone (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- [(trans)-13-fluoro-6,15,17- 206 triazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone PAT24007-WO-PCT Example No.Structure Name3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 207 piperidyl]-4-fluoro-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-12-one (rac)-3-fluoro-4-[1-[4- 208 (trifluoromethoxy)benzoyl]-4-piperidyl]-6,7,8,9- tetrahydro-5H-pyrido[2,3-b]indole-6-carbonitrile 1-[13-[1-[2-amino-4- 209 (trifluoromethoxy)benzoyl]-4-piperidyl]-12- fluoro-4,8,10-triazatricyclo[7.4.0.02,7]trideca- 1(9),2(7),10,12-tetraen-4-yl]ethanone 4-fluoro-11,11-dimethyl-3-[1-[4- 210 (trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-14-one 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- 211 piperidyl]-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2,4,6-tetraen-12-one PAT24007-WO-PCT Example No.Structure Name4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- 212 piperidyl]-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraen-13-one [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)- 15-fluoro-5-oxa-11,13- 213 diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)- 13-fluoro-6-oxa-15,17- 214 diazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4- [(trans)-15-fluoro-5-oxa-11,13- 215 diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4- [(trans)-15-fluoro-5-oxa-11,13- 216 diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)- 13-fluoro-6-oxa-15,17- 217 diazatetracyclo[8.7.0.03,8.011,16]heptadeca- 1(10),11,13,15-tetraen-12-yl]-1- piperidyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)- 15-fluoro-5-oxa-11,13- 218 diazatetracyclo[8.7.0.02,7.012,17]heptadeca- 1(10),12,14,16-tetraen-16-yl]-1- piperidyl]methanone, Isomer 2 [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4- 219 [4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[4- 220 [4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 [4-[6-amino-3-fluoro-6-(trifluoromethyl)- 221 5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Name[4-[6-amino-3-fluoro-6-(trifluoromethyl)- 222 5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 223 piperidyl]-4-fluoro-11,11-dimethyl-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-14-one [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4- 224 fluoro-14-oxa-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]methanone (rac)-[4-(4-fluoro-12-hydroxy-12-methyl-6,8- 225 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[2-amino-4-(pentafluoro-λ⁶- 226 sulfanyl)phenyl]-[4-(4-fluoro-13-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]methanone PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 227 fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[3- 228 fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H- pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone, Isomer 2 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- 229 piperidyl]-6,8,11- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-12-one (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 230 (3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,3'-tetrahydrofuran]-4-yl)-1- piperidyl]methanone (rac)-[4-(3-fluorospiro[5,7,8,9- 231 tetrahydropyrido[2,3-b]indole-6,3'- tetrahydrofuran]-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name[4-[3-fluoro-7-hydroxyimino-5,6,8,9- 232 tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluoro-7-hydroxyimino-5,6,8,9- 233 tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]- [4-(trifluoromethoxy)phenyl]methanone, Isomer 2 (rac)-[2-amino-4-(pentafluoro-λ⁶- 234 sulfanyl)phenyl]-[4-(4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]methanone 4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4- 235 piperidyl]-6,8,12- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-11-one [4-[3-fluoro-6-hydroxy-6-(trifluoromethyl)- 236 5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 PAT24007-WO-PCT Example No.Structure Name[4-[3-fluoro-6-hydroxy-6-(trifluoromethyl)- 237 5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 (rac)-[4-(4-fluoro-12-hydroxy-6,8- 238 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4-(pentafluoro-λ⁶- sulfanyl)phenyl]methanone (rac)-[4-(4-fluoro-13-hydroxy-6,8- 239 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4-(pentafluoro-λ⁶- sulfanyl)phenyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4- [(trans)-4-fluoro-13-oxa-6,8- 240 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4- [(trans)-4-fluoro-13-oxa-6,8- 241 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name(rac)-[4-(4-fluoro-6,8,13- 242 triazatetracyclo[7.7.0.02,7.011,15]hexadeca- 1(9),2,4,6-tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[4-(14-fluoro-4,10,12- 243 triazatetracyclo[7.7.0.02,6.011,16]hexadeca- 1(9),11,13,15-tetraen-15-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 244 piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,4'-pyrrolidine]-2'-one, Isomer 1 3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4- 245 piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,4'-pyrrolidine]-2'-one, Isomer 2 (rac)-[4-[6-amino-3-fluoro-6-(trifluoromethyl)- 246 5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name(rac)-[4-[3-fluoro-6-hydroxy-6- 247 (trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3- b]indol-4-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-[(cis)-7-fluoro-3,5- 248 diazatetracyclo[10.2.1.02,10.04,9]pentadeca- 2(10),4,6,8-tetraen-8-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[(cis)-7-fluoro-3,5- 249 diazatetracyclo[10.2.1.02,10.04,9]pentadeca- 2(10),4,6,8-tetraen-8-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)- 7-fluoro-3,5- 250 diazatetracyclo[10.2.1.02,10.04,9]pentadeca- 2(10),4,6,8-tetraen-8-yl]-1-piperidyl]methanone, Isomer 1 [4-[12-fluoro-4-(2,2,2-trifluoroethyl)-4,8,10- 251 triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11- tetraen-13-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3,6,6- 252 trifluoro-5,7,8,9-tetrahydropyrido[2,3-b]indol-4- yl)-1-piperidyl]methanone [2-amino-4-(trifluoromethoxy)phenyl]-[4-[12- 253 fluoro-4-(2,2,2-trifluoroethyl)-4,8,10- triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11- tetraen-13-yl]-1-piperidyl]methanone (rac)-[4-(12-fluoro-5,14,16- 254 triazatetracyclo[7.7.0.02,7.010,15]hexadeca- 1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-[(trans)-4-fluoro-13-oxa-6,8- 255 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[(trans)-4-fluoro-13-oxa-6,8- 256 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)- 4-fluoro-13-oxa-6,8- 257 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-(4- 258 fluoro-11-oxa-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl)-1-piperidyl]methanone [4-[(cis)-4-fluoro-13-oxa-6,8- 259 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 (rac)-4-[1-[2-amino-4- 260 (trifluoromethoxy)benzoyl]-4-piperidyl]-3- fluoro-spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,4'-pyrrolidine]-2'-one [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)- 4-fluoro-13-oxa-6,8- 261 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name(rac)-3-fluoro-4-[1-[4- 262 (trifluoromethoxy)benzoyl]-4- piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3- b]indole-6,4'-pyrrolidine]-2'-one [4-[4-fluoro-12-methoxy-6,8- 263 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[(4-fluoro-12-methoxy-6,8- 264 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 [4-[4-fluoro-13-methoxy-6,8- 265 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[4-fluoro-13-methoxy-6,8- 266 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 267 fluoro-13-methoxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 F O F F O N [4-[(cis)-4-fluoro-13-oxa-6,8- O 268 diazatetracyclo[7.6.0.02,7.011,15]pentadeca- F 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 N HNIsomer 24-fluoro-13-methyl-3-[1-[4- 269 (trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-14-one [4-(trifluoromethoxy)phenyl]-[4-(3,6,6-trifluoro- 270 5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl)-1- piperidyl]methanone 3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4- 271 piperidyl]-4-fluoro-6,8,14- triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-13-one PAT24007-WO-PCT Example No.Structure Name(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 272 (7-fluoro-3,5- diazatetracyclo[10.2.1.02,10.04,9]pentadeca- 2(10),4,6,8-tetraen-8-yl)-1-piperidyl]methanone (rac)-[4-(7-fluoro-3,5- 273 diazatetracyclo[10.2.1.02,10.04,9]pentadeca- 2(10),4,6,8-tetraen-8-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-[3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9- 274 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 1 [4-[3-fluoro-6-(oxetan-3-ylamino)-6,7,8,9- 275 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone, Isomer 2 (rac)-[4-[6-(cyclopropylamino)-3-fluoro-6,7,8,9- 276 tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 277 (4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]methanone (rac)-[4-(3-fluoro-6-hydroxy-6,7,8,9-tetrahydro- 278 5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[4-(11-fluorospiro[7,9- diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11- 279 tetraene-4,3'-tetrahydrofuran]-12-yl)-1- piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- (11-fluorospiro[7,9- 280 diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11- tetraene-4,3'-tetrahydrofuran]-12-yl)-1- piperidyl]methanone (rac)-[4-[(cis)-4-fluoro-6,8,13- 281 triazatetracyclo[7.6.0.02,7.011,15]pentadeca- 1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name(rac)-[4-(4-fluoro-12-hydroxy-6,8- 282 diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[4-(11-fluorospiro[7,9- 283 diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10- tetraene-4,3'-pyrrolidine]-12-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4- 284 (7-methoxy-6,7,8,9-tetrahydro-5H-pyrido[2,3- b]indol-4-yl)-1-piperidyl]methanone [4-(4-fluoro-6,8- 285 diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5,12-pentaen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone [4-(4-fluoro-6,8- 286 diazatricyclo[7.6.0.02,7]pentadeca-1(9),2,4,6- tetraen-3-yl)-1-piperidyl]-[4- (trifluoromethoxy)phenyl]methanone PAT24007-WO-PCT Example No.Structure Name[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(cis)- 7-fluoro-3,5- 287 diazatetracyclo[10.2.1.02,10.04,9]pentadeca- 2(10),4,6,8-tetraen-8-yl]-1-piperidyl]methanone, Isomer 2 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 288 fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[4- 289 fluoro-12-hydroxy-12-methyl-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 (rac)-4-fluoro-3-[1-[4- 290 (trifluoromethoxy)benzoyl]-4-piperidyl]-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraene-12-carbonitrile (rac)-3-[1-[2-amino-4- 291 (trifluoromethoxy)benzoyl]-4-piperidyl]-4- fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraene-13-carbonitrile PAT24007-WO-PCT Example No.Structure Name(rac)-3-[1-[2-amino-4- 292 (trifluoromethoxy)benzoyl]-4-piperidyl]-4- fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca- 1(9),2(7),3,5-tetraene-12-carbonitrile [2-amino-4-(trifluoromethoxy)phenyl]-[4-[12- 293 deuterio-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]methanone, Isomer 1 [2-amino-4-(trifluoromethoxy)phenyl]-[4-[12- 294 deuterio-4-fluoro-12-hydroxy-6,8- diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5- tetraen-3-yl]-1-piperidyl]methanone, Isomer 2 Table 1b: MASS: Example PreparationNMRLC / MS No.Method(m / z, [M+H]+) 1H NMR (400 MHz, DMSO-d6, 100°C) δ A + Ketal ppm 1.60 - 1.71 (m, 1 H) 1.72 - 1.92 (m, 3 H) deprotection 1.96 - 2.10 (m, 3 H) 2.63 (dd, J=14.1, 7.4 Hz, +reductive 1 1 H) 2.70 - 2.86 (m, 2 H) 2.97 - 3.20 (m, 6 H) amination + 3.49 - 3.61 (m, 1 H) 4.10 - 4.32 (m, 2 H) 4.50 523 chiral (dt, J=47.7, 5.3 Hz, 2 H) 7.41 (br d, J=8.4 Hz, separation 2 H) 7.57 (d, J=8.4 Hz, 2 H) 7.91 (d, J=4.3 Hz, 1 H) 10.97 (br s, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ A + ketal ppm 1.61 - 1.71 (m, 1 H) 1.73 - 1.93 (m, 3 H) deprotection 1.96 - 2.10 (m, 3 H) 2.63 (dd, J=14.1, 7.4 Hz, +reductive 1 H) 2.69 - 2.85 (m, 2 H) 2.97 - 3.21 (m, 6 H) amination + 3.49 - 3.61 (m, 1 H) 4.08 - 4.30 (m, 2 H) 4.50 523 chiral (dt, J=47.7, 5.3 Hz, 2 H) 7.41 (d, J=8.4 Hz, 2 separation H) 7.57 (br d, J=8.4 Hz, 2 H) 7.91 (d, J=4.3 Hz, 1 H) 10.97 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.74 - 1.89 (m, 3 H), 1.95 - 2.08 (m, 3 H), 2.63 (dd, J=7.4 and 16.6 Hz, 1 H), 2.82 - C 2.92 (m, 1 H), 2.98 - 3.03 (m partially hidden, 2 H), 3.10 (br t, J=12.7 Hz, 2 H), 3.52 - 3.61 478 (m, 1 H), 4.02 - 4.10 (m, 1 H), 4.11 - 4.29 (m, 2 H), 4.50 (br d, J=4.0 Hz, 1 H), 7.41 (br d, J=8.4 Hz, 2 H), 7.56 (br d, J=8.4 Hz, 2 H), 7.90 (d, J=4.3 Hz, 1 H), 10.94 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.86 (br d, J=12.7 Hz, 2 H), 1.91 - 2.05 (m, 2 H), 2.17 - 2.30 (m, 4 H), 2.87 - 2.91 (m A partially hidden, 2 H), 3.06 (t, J=12.7 Hz, 2 H), 3.65 - 3.75 (m, 1 H), 4.08 - 4.22 (m, 2 H), 491 7.38 (br d, J=8.4 Hz, 2 H), 7.55 (br d, J=8.4 Hz, 2 H), 7.97 (d, J=4.3 Hz, 1 H), 8.73 (br s, 1 H), 11.22 - 11.39 (m, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.25 - 1.37 (m, 1 H), 1.52 - 1.63 (m, 2 H), 1.76 - 1.92 (m, 3 H), 1.95 - 2.09 (m, 2 H), 2.35 - 2.45 (m, 3 H), 2.60 (td, J=2.5 and 12.2 A + N-BOC Hz, 1 H), 2.73 - 2.82 (m, 1 H), 2.87 - 2.94 (m deprotection partially hidden, 2 H), 3.00 - 3.18 (m, 3 H), 517 3.46 - 3.60 (m, 1 H), 4.07 - 4.28 (m, 2 H), 7.41 (br d, J=8.4 Hz, 2 H), 7.56 (br d, J=8.4 Hz, 2 H), 7.90 (d, J=4.3 Hz, 1 H), 10.95 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.79 - 1.90 (m, 2 H) 1.90 - 2.05 (m, 2 H) 2.62 - 2.79 (m, 2 H) 2.97 - 3.24 (m, 4 H) 3.25 A - 3.33 (m, 1 H) 3.62 - 3.74 (m, 2 H) 3.94 (t, J=6.4 Hz, 1 H) 4.16 - 4.33 (m, 2 H) 4.29 (br t, 490 J=6.4 Hz, 1 H) 7.43 (br d, J=8.4 Hz, 2 H) 7.58 (br d, J=8.4 Hz, 2 H) 7.98 (d, J=3.6 Hz, 1 H) 11.51 (br s, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.80 - 1.90 (m, 2 H) 1.91 - 2.05 (m, 2 H) 2.63 - 2.79 (m, 2 H) 2.97 - 3.19 (m, 4 H) 3.23 - 3.33 (m, 1 H) 3.61 - 3.73 (m, 2 H) 3.94 (t, D J=6.4 Hz, 1 H) 4.18 - 4.28 (m, 2 H) 4.30 (t, 505 J=6.4 Hz, 1 H) 5.39 (br s, 2 H) 6.52 (br d, J=8.4 Hz, 1 H) 6.71 (br s, 1 H) 7.16 (d, J=8.4 Hz, 1 H) 7.97 (d, J=3.6 Hz, 1 H) 11.50 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.60 - 1.74 (m, 2 H), 1.86 (br d, J=12.7 Hz, 2 H), 1.98 - 2.11 (m, 4 H), 2.61 - 2.79 (m, D + OTBS 2 H), 2.97 - 3.01 (m partially hidden, 1 H), deprotection 3.04 - 3.20 (m, 3 H), 3.62 - 3.75 (m, 1 H), + chiral 3.87 - 3.97 (m, 1 H), 4.19 (br d, J=12.7 Hz, 2 507 separation H), 4.24 (br d, J=4.3 Hz, 1 H), 5.35 (br s, 2 H), 6.51 (br d, J=8.4 Hz, 1 H), 6.70 (br s, 1 H), 7.13 (d, J=8.4 Hz, 1 H), 7.89 (d, J=4.3 Hz, 1 H), 11.01 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.59 - 1.75 (m, 2 H), 1.86 (br d, J=12.7 Hz, 2 H), 1.98 - 2.12 (m, 4 H), 2.61 - 2.79 (m, D + OTBS 2 H), 2.97 - 3.00 (m partially hidden, 1 H), deprotection 3.04 - 3.20 (m, 3 H), 3.62 - 3.74 (m, 1 H), + chiral 3.88 - 3.96 (m, 1 H), 4.19 (br d, J=12.7 Hz, 2 507 separation H), 4.24 (br d, J=4.3 Hz, 1 H), 5.35 (br s, 2 H), 6.51 (br d, J=8.4 Hz, 1 H), 6.70 (br s, 1 H), 7.13 (d, J=8.4 Hz, 1 H), 7.89 (d, J=4.3 Hz, 1 H), 11.02 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 0.23 - 0.32 (m, 2 H) 0.38 - 0.46 (m, 2 H) A+ ketal 1.59 - 1.73 (m, 1 H) 1.85 (br t, J=12.7 Hz, 2 deprotection H) 1.93 - 2.13 (m, 4 H) 2.21 (tt, J=6.7, 3.5 + reductive Hz, 1 H) 2.60 - 2.68 (m, 1 H) 2.68 - 2.79 (m, amination + 2 H) 3.00 - 3.11 (m, 3 H) 3.17 (dd, J=14.4, 517 chiral 5.2 Hz, 1 H) 3.49 - 3.61 (m, 1 H) 4.10 - 4.29 separation (m, 2 H) 7.39 (d, J=8.4 Hz, 2 H) 7.54 (d, J=8.4 Hz, 2 H) 7.88 (d, J=4.3 Hz, 1 H) 10.93 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 0.24 - 0.31 (m, 2 H) 0.38 - 0.46 (m, 2 H) A+ ketal 1.60 - 1.73 (m, 1 H) 1.85 (br t, J=12.7 Hz, 2 deprotection H) 1.93 - 2.17 (m, 4 H) 2.21 (tt, J=6.7, 3.5 + reductive Hz, 1 H) 2.61 - 2.69 (m, 1 H) 2.69 - 2.85 (m, amination + 2 H) 3.00 - 3.12 (m, 3 H) 3.17 (dd, J=14.4, 517 chiral 5.2 Hz, 1 H) 3.48 - 3.61 (m, 1 H) 4.08 - 4.26 separation (m, 2 H) 7.39 (d, J=8.4 Hz, 2 H) 7.54 (d, J=8.4 Hz, 2 H) 7.88 (d, J=4.3 Hz, 1 H) 10.93 (br s, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.67 (t, J=5.4 Hz, 4 H) 1.82 (br d, J=12.7 Hz, 2 H) 1.91 - 2.05 (m, 2 H) 2.77 (s, 2 H) A+ NBOC 2.78 - 2.91 (m, 4 H) 2.83 (br s, 2 H) 3.13 (br t, deprotection J=12.7 Hz, 2 H) 3.32 - 3.48 (m, 1 H) 4.10 - 517 4.33 (m, 2 H) 7.43 (br d, J=8.4 Hz, 2 H) 7.58 (d, J=8.4 Hz, 2 H) 7.91 (d, J=3.4 Hz, 1 H) 11.02 - 11.21 (m, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.87 - 1.94 (m, 2 H) 1.99 - 2.10 (m, 2 H) 2.13 (t, J=6.3 Hz, 2 H) 2.80 (t, J=6.3 Hz, 2 H) A 3.13 - 3.20 (m, 2 H) 3.20 (s, 2 H) 3.54 - 3.64 (m, 1 H) 4.13 - 4.31 (m, 2 H) 4.40 (d, J=5.6 504 Hz, 2 H) 4.45 (d, J=5.6 Hz, 2 H) 7.42 (d, J=8.4 Hz, 2 H) 7.58 (d, J=8.4 Hz, 2 H) 7.92 (d, J=4.3 Hz, 1 H) 11.03 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.71 - 1.87 (m, 3 H), 1.93 - 2.07 (m, 3 H), 2.60 (dd, J=7.4 and 16.6 Hz, 1 H), 2.80 - 2.88 (m, 1 H), 2.94 - 3.01 (m partially hidden, C + OTBS 2 H), 3.06 (br t, J=12.7 Hz, 2 H), 3.47 - 3.56 deprotection (m, 1 H), 3.98 - 4.07 (m, 1 H), 4.16 (br d, 493 J=12.7 Hz, 2 H), 4.47 (d, J=4.0 Hz, 1 H), 5.33 (br s, 2 H), 6.49 (br d, J=8.4 Hz, 1 H), 6.68 (br s, 1 H), 7.11 (d, J=8.4 Hz, 1 H), 7.87 (d, J=4.3 Hz, 1 H), 10.90 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.86 (br d, J=12.7 Hz, 2 H), 1.94 - 2.09 (m, 4 H), 2.93 (br s partially hidden, 2 H), B 2.98 - 3.02 (m partially hidden, 2 H), 3.05 - 3.16 (m, 2 H), 3.50 - 3.60 (m, 1 H), 3.98 (br s, 520 4 H), 4.09 - 4.28 (m, 2 H), 7.41 (d, J=7.7 Hz, 2 H), 7.56 (d, J=7.7 Hz, 2 H), 7.93 (d, J=4.3 Hz, 1 H), 10.97 - 11.03 (m, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.87 (br d, J=12.7 Hz, 2 H) 1.93 - 2.08 (m, 2 H) 2.71 (t, J=6.8 Hz, 2 H) 3.09 (br t, B + Ketal J=12.7 Hz, 2 H) 3.25 (t, J=6.8 Hz, 2 H) 3.48 - deprotection 3.58 (m, 1 H) 3.62 (s, 2 H) 4.11 - 4.24 (m, 2 476 H) 7.39 (br d, J=8.4 Hz, 2 H) 7.54 (d, J=8.4 Hz, 2 H) 7.97 (d, J=4.3 Hz, 1 H) 11.11 - 11.20 (m, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.31 (s, 3 H) 1.71 - 1.80 (m, 1 H) 1.80 - A + ketal 1.90 (m, 3 H) 1.97 - 2.10 (m, 2 H) 2.62 - 2.70 deprotection (m, 1 H) 2.83 - 2.93 (m, 1 H) 2.89 (s, 2 H) + MeMgBr 3.05 - 3.15 (m, 2 H) 3.47 - 3.58 (m, 1 H) 4.07 492 addition (br s, 1 H) 4.14 - 4.29 (m, 2 H) 7.41 (br d, J=8.4 Hz, 2 H) 7.57 (br d, J=8.4 Hz, 2 H) 7.90 (d, J=4.3 Hz, 1 H) 10.91 - 11.00 (m, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.82 (br d, J=12.7 Hz, 2 H), 1.89 - 2.03 (m, 2 H), 2.09 (t, J=7.1 Hz, 2 H), 2.95 - 3.05 D + chiral (m partially hidden, 4 H), 3.10 (br t, J=12.7 separation Hz, 2 H), 3.29 - 3.44 (m, 1 H), 3.71 (s, 2 H), 519 3.86 - 3.95 (m, 2 H), 4.14 - 4.26 (m, 2 H), 5.37 (br s, 2 H), 6.51 (br d, J=8.4 Hz, 1 H), 6.71 (br s, 1 H), 7.15 (d, J=8.4 Hz, 1 H), 7.93 (d, J=3.3 Hz, 1 H), 11.20 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.82 (br d, J=12.7 Hz, 2 H), 1.90 - 2.03 (m, 2 H), 2.09 (t, J=7.1 Hz, 2 H), 2.95 - 3.05 D + chiral (m partially hidden, 4 H), 3.10 (br t, J=12.7 separation Hz, 2 H), 3.29 - 3.42 (m, 1 H), 3.71 (s, 2 H), 519 3.86 - 3.95 (m, 2 H), 4.14 - 4.26 (m, 2 H), 5.37 (br s, 2 H), 6.51 (br d, J=8.4 Hz, 1 H), 6.71 (br s, 1 H), 7.15 (d, J=8.4 Hz, 1 H), 7.93 (d, J=3.3 Hz, 1 H), 11.20 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.89 (br d, J=12.7 Hz, 2 H), 1.95 - 2.08 (m, 2 H), 2.13 (s, 3 H), 2.79 - 2.86 (m A partially hidden, 2 H), 3.10 (br t, J=12.7 Hz, 2 H), 3.21 - 3.32 (m, 1 H), 3.80 (t, J=5.6 Hz, 2 505 H), 4.12 - 4.27 (m, 2 H), 4.82 (br s, 2 H), 7.39 (br d, J=8.4 Hz, 2 H), 7.56 (br d, J=8.4 Hz, 2 H), 7.96 (d, J=4.3 Hz, 1 H), 11.20 - 11.29 (m, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.83 (br d, J=12.7 Hz, 2 H), 1.89 - 2.04 (m, 2 H), 2.09 (t, J=7.1 Hz, 2 H), 2.95 - 2.97 A + chiral (m partially hidden, 2 H), 2.98 - 3.06 (m, 2 separation H), 3.12 (br t, J=12.7 Hz, 2 H), 3.34 - 3.45 504 (m, 1 H), 3.67 - 3.75 (m, 2 H), 3.86 - 3.97 (m, 2 H), 4.10 - 4.32 (m, 2 H), 7.41 (br d, J=8.4 Hz, 2 H), 7.57 (br d, J=8.4 Hz, 2 H), 7.93 (d, J=3.3 Hz, 1 H), 11.21 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.83 (br d, J=12.7 Hz, 2 H), 1.90 - 2.04 (m, 2 H), 2.09 (t, J=7.1 Hz, 2 H), 2.95 - 2.97 A + chiral (m partially hidden, 2 H), 2.98 - 3.07 (m, 2 separation H), 3.12 (br t, J=12.7 Hz, 2 H), 3.34 - 3.43 504 (m, 1 H), 3.69 - 3.74 (m, 2 H), 3.87 - 3.96 (m, 2 H), 4.06 - 4.33 (m, 2 H), 7.41 (br d, J=8.4 Hz, 2 H), 7.57 (br d, J=8.4 Hz, 2 H), 7.93 (br d, J=3.3 Hz, 1 H), 11.21 (br s, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.58 - 1.70 (m, 1 H) 1.72 - 1.90 (m, 3 H) A + ketal 1.96 - 2.07 (m, 3 H) 2.61 (dd, J=14.1, 7.4 Hz, deprotection 1 H) 2.69 - 2.85 (m, 2 H) 2.94 - 3.18 (m, 6 H) + reductive 3.47 - 3.61 (m, 1 H) 4.05 - 4.29 (m, 2 H) 4.48 523 amination (dt, J=47.7, 5.3 Hz, 2 H) 7.39 (br d, J=8.4 Hz, 2 H) 7.54 (br d, J=8.4 Hz, 2 H) 7.88 (d, J=4.3 Hz, 1 H) 10.95 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.56 - 1.69 (m, 1 H) 1.79 - 2.09 (m, 5 H) A + ketal 2.27 - 2.37 (m, 1 H) 2.54 - 2.64 (m, 2 H) 2.69 deprotection - 2.83 (m, 2 H) 3.00 - 3.14 (m, 3 H) 3.41 - + reductive 3.60 (m, 1 H) 4.07 - 4.16 (m, 1 H) 4.15 - 4.28 533 amination (m, 2 H) 4.35 - 4.41 (m, 2 H) 4.70 (t, J=6.2 Hz, 2 H) 7.41 (br d, J=8.4 Hz, 2 H) 7.57 (d, J=8.4 Hz, 2 H) 7.90 (d, J=4.3 Hz, 1 H) 10.96 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.73 (br d, J=12.7 Hz, 2 H) 2.03 - 2.11 (m, 2 H) 2.12 - 2.24 (m, 2 H) 2.80 (t, J=6.5 E Hz, 2 H) 2.99 - 3.08 (m, 2 H) 3.52 - 3.61 (m, 1 H) 4.14 - 4.24 (m, 4 H) 5.35 (br s, 2 H) 6.52 479 (br d, J=8.4 Hz, 1 H) 6.70 (br s, 1 H) 7.15 (d, J=8.4 Hz, 1 H) 7.93 (d, J=3.4 Hz, 1 H) 10.74 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.71 (br d, J=12.7 Hz, 2 H) 2.01 - 2.10 (m, 2 H) 2.10 - 2.22 (m, 2 H) 2.79 (t, J=6.5 E Hz, 2 H) 2.99 - 3.11 (m, 2 H) 3.52 - 3.63 (m, 464 1 H) 4.06 - 4.27 (m, 4 H) 7.40 (br d, J=8.4 Hz, 2 H) 7.54 (br d, J=8.4 Hz, 2 H) 7.92 (d, J=3.4 Hz, 1 H) 10.73 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.80 - 1.91 (m, 2 H) 1.93 - 2.09 (m, 2 H) A 2.67 - 2.75 (m, 1 H) 3.01 - 3.21 (m, 4 H) 3.46 - 3.61 (m, 3 H) 3.91 - 4.02 (m, 2 H) 4.06 - 490 4.12 (m, 1 H) 4.14 - 4.30 (m, 2 H) 7.42 (br d, J=8.4 Hz, 2 H) 7.56 (br d, J=8.4 Hz, 2 H) 7.93 (d, J=3.8 Hz, 1 H) 11.17 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.80 - 1.90 (m, 2 H) 1.92 - 2.08 (m, 2 H) 2.67 - 2.75 (m, 1 H) 2.99 - 3.22 (m, 4 H) 3.46 D - 3.61 (m, 3 H) 3.90 - 4.01 (m, 2 H) 4.06 - 4.12 (m, 1 H) 4.15 - 4.28 (m, 2 H) 5.36 (br s, 505 2 H) 6.51 (br d, J=8.4 Hz, 1 H) 6.71 (br s, 1 H) 7.14 (d, J=8.4 Hz, 1 H) 7.92 (d, J=3.8 Hz, 1 H) 11.16 (br s, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.85 (br d, J=12.7 Hz, 2 H), 1.92 - 2.06 (m, 2 H), 2.93 - 2.95 (m partially hidden, 2 + NHBOC H), 3.01 - 3.11 (m, 2 H), 3.39 - 3.49 (m, 1 H), deprotection 3.94 (t, J=5.6 Hz, 2 H), 4.17 (br d, J=12.7 Hz, 479 2 H), 4.71 (br s, 2 H), 5.33 (br s, 2 H), 6.49 (br d, J=8.4 Hz, 1 H), 6.68 (br s, 1 H), 7.11 (d, J=8.4 Hz, 1 H), 7.94 (d, J=4.3 Hz, 1 H), 11.01 - 11.12 (m, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.87 (br d, J=12.7 Hz, 2 H) 1.95 - 2.08 (m, 2 H) 2.10 (t, J=6.3 Hz, 2 H) 2.77 (t, J=6.3 D Hz, 2 H) 3.13 (br t, J=12.7 Hz, 2 H) 3.18 (s, 2 H) 3.49 - 3.60 (m, 1 H) 4.19 (br d, J=12.7 Hz, 519 2 H) 4.38 (d, J=5.6 Hz, 2 H) 4.43 (d, J=5.6 Hz, 2 H) 5.34 (br s, 2 H) 6.49 (br d, J=8.4 Hz, 1 H) 6.69 (br s, 1 H) 7.13 (d, J=8.4 Hz, 1 H) 7.89 (d, J=4.3 Hz, 1 H) 11.00 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.88 (br d, J=12.7 Hz, 2 H) 1.98 - 2.13 (m, 2 H) 2.93 - 2.95 (m hidden, 2 H) 3.09 (br D t, J=12.7 Hz, 2 H) 3.54 (br q, J=5.8 Hz, 2 H) 3.57 - 3.66 (m, 1 H) 3.91 (s, 2 H) 4.19 (br d, 506 J=12.7 Hz, 2 H) 5.34 (br s, 2 H) 6.48 (br d, J=8.4 Hz, 1 H) 6.68 (br s, 1 H) 7.14 (d, J=8.4 Hz, 1 H) 7.35 (br t, J=5.8 Hz, 1 H) 7.93 (d, J=4.3 Hz, 1 H) 11.22 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.87 (br d, J=12.7 Hz, 2 H) 1.97 - 2.09 (m, 2 H) 2.75 (br t, J=6.5 Hz, 2 H) 3.01 (t, D J=6.5 Hz, 2 H) 3.08 (br t, J=12.7 Hz, 2 H) 3.35 - 3.43 (m, 1 H) 4.17 (br d, J=12.7 Hz, 2 506 H) 4.55 (d, J=5.8 Hz, 2 H) 5.34 (br s, 2 H) 6.49 (br d, J=8.4 Hz, 1 H) 6.68 (br s, 1 H) 7.12 (d, J=8.4 Hz, 1 H) 7.51 (br t, J=5.8 Hz, 1 H) 7.93 (d, J=4.3 Hz, 1 H) 11.23 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.73 - 1.88 (m, 3 H), 1.92 - 2.08 (m, 3 A + ketal H), 2.65 - 2.86 (m, 3 H), 3.07 (br t, J=12.7 deprotection Hz, 2 H), 3.14 (br dd, J=5.1 and 15.4 Hz, 1 + Reduction H), 3.46 - 3.58 (m, 1 H), 3.96 - 4.10 (m, 1 H), 478 + Chiral 4.11 - 4.25 (m, 2 H), 4.41 (d, J=4.0 Hz, 1 H), separation 7.39 (br d, J=8.4 Hz, 2 H), 7.55 (d, J=8.4 Hz, 2 H), 7.88 (d, J=4.3 Hz, 1 H), 10.94 (br s, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.73 - 1.88 (m, 3 H), 1.92 - 2.08 (m, 3 A + ketal H), 2.65 - 2.86 (m, 3 H), 3.07 (br t, J=12.7 deprotection Hz, 2 H), 3.14 (br dd, J=5.1 and 15.4 Hz, 1 + reduction + H), 3.47 - 3.58 (m, 1 H), 3.97 - 4.09 (m, 1 H), 478 chiral 4.10 - 4.27 (m, 2 H), 4.38 - 4.46 (m, 1 H), separation 7.39 (br d, J=8.4 Hz, 2 H), 7.55 (d, J=8.4 Hz, 2 H), 7.88 (d, J=4.3 Hz, 1 H), 10.96 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ A + NBOC ppm 1.80 - 1.91 (m, 2 H) 1.95 - 2.11 (m, 2 H) deprotection 2.12 - 2.27 (m, 1 H) 2.60 - 2.72 (m, 3 H) 2.99 + chiral - 3.17 (m, 4 H) 3.18 - 3.41 (m, 3 H) 3.69 - 489 separation 3.80 (m, 1 H) 4.12 - 4.36 (m, 2 H) 7.41 (br d, J=8.4 Hz, 2 H) 7.57 (br d, J=8.4 Hz, 2 H) 7.90 (d, J=4.0 Hz, 1 H) 11.00 - 11.14 (m, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ A + NBOC ppm 1.80 - 1.91 (m, 2 H) 1.95 - 2.11 (m, 2 H) deprotection 2.11 - 2.28 (m, 1 H) 2.60 - 2.71 (m, 3 H) 2.99 + chiral - 3.17 (m, 4 H) 3.18 - 3.41 (m, 3 H) 3.70 - 489 separation 3.80 (m, 1 H) 4.12 - 4.35 (m, 2 H) 7.41 (br d, J=8.4 Hz, 2 H) 7.57 (br d, J=8.4 Hz, 2 H) 7.90 (d, J=4.0 Hz, 1 H) 11.00 - 11.14 (m, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.88 (br d, J=12.7 Hz, 2 H) 1.96 - 2.10 (m, 2 H) 2.75 (br t, J=6.5 Hz, 2 H) 3.01 (br t, A J=6.5 Hz, 2 H) 3.09 (br t, J=12.7 Hz, 2 H) 3.36 - 3.47 (m, 1 H) 4.08 - 4.28 (m, 2 H) 4.56 491 (d, J=5.8 Hz, 2 H) 7.40 (br d, J=8.4 Hz, 2 H) 7.51 (br t, J=5.8 Hz, 1 H) 7.55 (d, J=8.4 Hz, 2 H) 7.94 (d, J=4.3 Hz, 1 H) 11.26 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.88 (br d, J=12.7 Hz, 2 H), 2.01 - 2.14 (m, 2 H), 2.90 - 2.93 (m hidden, 2 H), 3.11 (br A t, J=12.7 Hz, 2 H), 3.54 (br q, J=5.8 Hz, 2 H), 3.58 - 3.69 (m, 1 H), 3.92 (s, 2 H), 4.08 - 4.28 491 (m, 2 H), 7.32 - 7.38 (m, 1 H), 7.39 (br d, J=8.4 Hz, 2 H), 7.57 (br d, J=8.4 Hz, 2 H), 7.95 (d, J=4.3 Hz, 1 H), 11.24 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.79 - 1.94 (m, 3 H), 1.94 - 2.09 (m, 3 H), 2.65 - 2.73 (m, 1 H), 2.80 - 2.90 (m, 1 H), C 2.96 - 3.14 (m partially hidden, 4 H), 3.34 (s, 3 H), 3.48 - 3.58 (m, 1 H), 3.70 - 3.76 (m, 1 492 H), 4.05 - 4.29 (m, 2 H), 7.39 (br d, J=8.4 Hz, 2 H), 7.54 (d, J=8.4 Hz, 2 H), 7.90 (d, J=4.3 Hz, 1 H), 10.97 (br s, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.48 - 1.57 (m, 4 H) 1.80 (t, J=6.5 Hz, 2 H) 1.88 (br d, J=12.7 Hz, 2 H) 1.98 - 2.10 (m, A 2 H) 2.73 (t, J=6.5 Hz, 2 H) 2.82 (s, 2 H) 3.13 (br t, J=12.7 Hz, 2 H) 3.54 - 3.62 (m, 1 H) 532 3.63 - 3.69 (m, 4 H) 4.10 - 4.34 (m, 2 H) 7.42 (br d, J=8.4 Hz, 2 H) 7.57 (br d, J=8.4 Hz, 2 H) 7.91 (d, J=4.3 Hz, 1 H) 11.00 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.47 - 1.58 (m, 4 H) 1.80 (t, J=6.5 Hz, 2 H) 1.87 (br d, J=12.7 Hz, 2 H) 1.95 - 2.12 (m, D 2 H) 2.73 (t, J=6.5 Hz, 2 H) 2.82 (s, 2 H) 3.11 (br t, J=12.7 Hz, 2 H) 3.51 - 3.61 (m, 1 H) 547 3.61 - 3.72 (m, 4 H) 4.21 (br d, J=12.7 Hz, 2 H) 5.36 (br s, 2 H) 6.51 (br d, J=8.4 Hz, 1 H) 6.71 (br s, 1 H) 7.15 (d, J=8.4 Hz, 1 H) 7.90 (d, J=4.3 Hz, 1 H) 10.98 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.69 - 1.77 (m, 4 H) 1.82 (br d, J=12.7 Hz, 2 H) 1.90 - 2.03 (m, 2 H) 2.83 (s, 2 H) D 2.87 (s, 2 H) 3.11 (br t, J=12.7 Hz, 2 H) 3.31 - 3.43 (m, 1 H) 3.63 - 3.76 (m, 4 H) 4.21 (br d, 533 J=12.7 Hz, 2 H) 5.41 (br s, 2 H) 6.52 (br d, J=8.4 Hz, 1 H) 6.72 (br s, 1 H) 7.16 (d, J=8.4 Hz, 1 H) 7.91 (d, J=3.4 Hz, 1 H) 11.16 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.59 - 1.72 (m, 2 H), 1.84 (br d, J=12.7 A + OTBS Hz, 2 H), 1.96 - 2.10 (m, 4 H), 2.60 - 2.78 (m, deprotection 2 H), 2.93 - 3.00 (m partially hidden, 1 H), + chiral 3.05 - 3.19 (m, 3 H), 3.63 - 3.73 (m, 1 H), 492 separation 3.85 - 3.95 (m, 1 H), 4.08 - 4.30 (m, 3 H), 7.39 (br d, J=8.4 Hz, 2 H), 7.54 (br d, J=8.4 Hz, 2 H), 7.88 (d, J=4.3 Hz, 1 H), 11.00 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.58 - 1.72 (m, 2 H), 1.84 (br d, J=12.7 A + OTBS Hz, 2 H), 1.96 - 2.09 (m, 4 H), 2.60 - 2.77 (m, deprotection 2 H), 2.94 - 2.99 (m partially hidden, 1 H), + chiral 3.04 - 3.20 (m, 3 H), 3.62 - 3.73 (m, 1 H), 492 separation 3.84 - 3.95 (m, 1 H), 4.07 - 4.30 (m, 3 H), 7.39 (br d, J=8.4 Hz, 2 H), 7.54 (d, J=8.4 Hz, 2 H), 7.88 (d, J=4.3 Hz, 1 H), 11.00 (br s, 1 H) PAT24007-WO-PCT 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.81 - 1.95 (m, 3 H) 1.96 - 2.10 (m, 3 H) 2.67 - 2.74 (m, 1 H) 2.83 - 2.90 (m partially + NHBOC hidden, 1 H) 3.01 - 3.14 (m partially hidden, 4 deprotection H) 3.36 (s, 3 H) 3.47 - 3.59 (m, 1 H) 3.71 - 507 3.80 (m, 1 H) 4.14 - 4.23 (m, 2 H) 5.36 (br s, 2 H) 6.51 (br d, J=8.4 Hz, 1 H) 6.70 (br s, 1 H) 7.13 (br d, J=8.4 Hz, 1 H) 7.91 (br s, 1 H) 10.98 (br s, 1 H) 1H NMR (400 MHz, DMSO-d6, 100°C) δ ppm 1.54 - 1.76 (m, 2 H), 1.85 - 1.95 (m, 3 H), 1.99 - 2.16 (m, 3 H), 2.71 - 2.90 (m, 2 H), 2.90 - 2.97 (m partially hidden, 1 H), 3.04 - D + OTBS 3.18 (m, 2 H), 3.25 - 3.34 (m, 1 H), 3.67 - deprotection 3.77 (m, 2 H), 4.20 (br d, J=12.7 Hz, 2 H), 507 4.28 (d, J=3.9 Hz, 1 H), 5.35 (br s, 2 H), 6.51 (br d, J=8.4 Hz, 1 H), ...

Claims

1. A compound, being of Formula (I)or a pharmaceutically acceptable salt thereof, wherein:ring A is (C5-C8)cycloalkane, (C6-C8)cycloalkene, or 5- to 8-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RA,wherein RA at each occurrence is:(a) independently selected from -D, halo, OH, oxo, =NOH, NHR’, CN, C(O)R’’, (C1-C3)alkyl, O(C1-C3)alkyl, (C3-C6)cycloalkyl, and 3- to 6-membered heterocycloalkyl, wherein each occurrence of (C1-C3)alkyl is optionally substituted with one or more groups selected from halo and -OH,wherein each R’ is selected from -H, (C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and 3- to 4-membered heterocycloalkyl,wherein each R’’ is selected from -OH, -O(C1-C3)alkyl, and (C1-C3)alkyl (e.g. -CH3); and / or(b) taken together with another occurrence of RAand the intervening atom(s) to form a (C4-C7)cycloalkyl or 4- to 7-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring and said cycloalkyl ring are optionally substituted by one or more groups selected from oxo, C(O)OH, C(O)N((C1-C3)alkyl)2, and (C1-C3)alkyl;R1 is selected from -H, and halo (e.g., -F);R2 is -(C6-C10)aryl, wherein R2 is substituted with one, or two occurrences of RB,wherein each RB is independently selected from halo, -OH, -NH2, -SF5, -(C1-C3)alkyl, and -O(C1-C3)alkyl, wherein each occurrence of -(C1-C3)alkyl and O(C1-C3)alkyl is optionally substituted by one or more halo; andn is 0, 1, or 2,with the proviso that when R2 is 4-(pentafluorosulfanyl)phenyl, R1 is -H, and n is 1, then ring A is not unsubstituted cyclopentane.

2. The compound of claim 1, wherein ring A is selected from cyclopentane, cyclohexane, cycloheptane, cyclooctane, tetrahydrofuran, tetrahydropyran, piperidine, morpholine, oxepane, azepane, 1,4-oxazepane, and thiepane, wherein ring A is optionally substituted with one or more occurrences of RA as defined in claim 1.

3. The compound of claim 1 or claim 2, wherein ring Ais selected from: , , , , , , , ,, , , , , ,,, , ,, and , wherein the dashed bonds indicate the points of fusion to the pyrrole ring, wherein ring A is optionally substituted by one or more occurrences of RA as defined in claim 1.

4. The compound of any one of claims 1-3, wherein R2 is selected from: , , , and .

5. A compound, being of Formula (II)or a pharmaceutically acceptable salt thereof, wherein:ring A is (C5-C8)cycloalkane or 6- to 7-membered heterocycloalkane, wherein ring A is optionally substituted with one or more occurrences of RA,wherein RA at each occurrence is:(a) independently selected from OH, oxo, NHR’, C(O)CH3, (C1-C3)alkyl, and O(C1-C3)alkyl,wherein each R’ is selected from (C1-C3)alkyl optionally substituted with one or more halo, -(C3-C4)cycloalkyl, and 3- to 4-membered heterocycloalkyl; or(b) taken together with another occurrence of RAand the intervening atom(s) to form a (C5-C7)cycloalkyl or 4- to 6-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted by oxo;R1 is selected from -H, and -F;RB1 is selected from -H, and -NH2; andRB2 is selected from -OCF3, and -SF5,with the proviso that when RB1 is -H, RB2 is -SF5, and R1 is -H, then ring A is not unsubstituted cyclopentane.

6. The compound of claim 5, wherein ring A is selected from: , , , , , , , , , and , wherein the dashed bonds indicate the points of fusion to the pyrrole ring, wherein ring A is optionally substituted by one or more occurrences of RA as defined in any one of the preceding claims.

7. The compound of claim 5 or claim 6, wherein RB2 is -OCF3.

8. The compound of any one of claims 1-7, wherein R1 is -F.

9. A compound, being of Formula (III), Formula (IV), Formula (V), or Formula (VI): or a pharmaceutically acceptable salt thereof, wherein ring A and R1 are as defined in any one of the preceding claims, with the proviso that when the compound is a compound of Formula (V) and R1 is -H, then ring A is not unsubstituted cyclopentane.

10. A compound selected from the group consisting of:[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone; [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl)-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-(12-fluoro-5-oxa-8,10-diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-13-yl)-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluorospiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-oxetane]-4-yl)-1-piperidyl]methanone;[4-[(12R)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone; [4-[(12S)-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;(rac)-[4-(4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-5,7,8,9-tetrahydropyrido[2,3-b]indol-6-one;[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone;(6R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one;(6S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4’-pyrrolidine]-2’-one;[4-[(3R,8R)-13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-[(3S,8S)-13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-((2S, 7S)-12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-((2R, 7R)-12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl)-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-oxa-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone;3-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-4-fluoro-13-methyl-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4-fluoro-13-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4-fluoro-13-methoxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-6,8-diazatricyclo[7.6.0.02,7]pentadeca-1(9),2,4,6-tetraen-3-yl)-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-6-(1-hydroxy-1-methyl-ethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;(7R)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile;(7S)-4-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]-3-fluoro-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indole-7-carbonitrile;[2-amino-4-(trifluoromethoxy)phenyl]-[4-(3-fluoro-1'-methyl-spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,3'-azetidine]-4-yl)-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6E)-3-fluoro-6-hydroxyimino-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6Z)-3-fluoro-6-hydroxyimino-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[4-[(5R)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-[(5S)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7E)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7Z)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12E)-4-fluoro-12-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12Z)-4-fluoro-12-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13E)-4-fluoro-13-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13Z)-4-fluoro-13-hydroxyimino-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(5R)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(5S)-3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3R,8R)-13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1-piperidyl]methanone; [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(3S,8S))-13-fluoro-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-12-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7R)-12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7S)-12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1-piperidyl]methanone; [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2S,7R)-12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(2R,7S)-12-fluoro-5,14,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-1(9),10,12,14-tetraen-11-yl]-1-piperidyl]methanone;[4-[(6R)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-[(6S)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[4-[(12R)-4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-[(12S)-4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7R)-3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(7S)-3-fluoro-7-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;1-[4-fluoro-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-13-yl]ethanone; [2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13R)-4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(13S)-4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl)-1-piperidyl]methanone;(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-7-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[3-fluoro-5-(hydroxymethyl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[4-[(13R)-4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-[(13S)-4-fluoro-13-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;4-fluoro-11,11-dimethyl-3-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]-6,8,13-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-14-one;[4-[(6R)-6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-[(6S)-6-amino-3-fluoro-6-(trifluoromethyl)-5,7,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6R)-3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(6S)-3-fluoro-6-hydroxy-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-4-yl]-1-piperidyl]methanone;[4-[(7E)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[4-[(7Z)-3-fluoro-7-hydroxyimino-5,6,8,9-tetrahydropyrido[2,3-b]indol-4-yl]-1-piperidyl]-[4-(trifluoromethoxy)phenyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11R,15S)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(11S,15R)-4-fluoro-13-oxa-6,8-diazatetracyclo[7.6.0.02,7.011,15]pentadeca-1(9),2,4,6-tetraen-3-yl]-1-piperidyl]methanone;(6R)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one;(6S)-3-fluoro-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidyl]spiro[5,7,8,9-tetrahydropyrido[2,3-b]indole-6,4'-pyrrolidine]-2'-one;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-4-fluoro-12-hydroxy-12-methyl-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone;[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12R)-12-deuterio-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone; and[2-amino-4-(trifluoromethoxy)phenyl]-[4-[(12S)-12-deuterio-4-fluoro-12-hydroxy-6,8-diazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5-tetraen-3-yl]-1-piperidyl]methanone,and the pharmaceutically acceptable salts thereof.

11. A pharmaceutical composition comprising the compound of any one of claims 1-10 and at least one pharmaceutically acceptable excipient or carrier.

12. A compound according to any one of claims 1-10, or a pharmaceutical composition according to claim 11, for use in therapy.

13. A compound according to any one of claims 1-10, or a pharmaceutical composition according to claim 11, for use in the treatment or prevention of cancer.

14. The compound or pharmaceutical composition for use according to claim 13, wherein the cancer is characterized by increased MAPK7 expression and / or increased ERK5 activity.

15. The compound or pharmaceutical composition for use according to claim 13 or claim 14, wherein the cancer is selected from leukaemia, breast cancer, multiple myeloma, colon cancer, colorectal cancer, lung cancer, pancreatic cancer, renal cell carcinoma, mesothelioma, adenocarcinoma, neuroblastoma, melanoma, and hepatocellular carcinoma. 

Images